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Abstract 
The role of SIRT1 in skeletal muscle function and repair of older mice 
 
Matthew John Myers 
 
Human skeletal muscle is a highly metabolic tissue necessary for mobility and 
coordination. Responsible for approximately one-fifth of the resting human metabolism, skeletal 
muscle is also an important regulator of metabolites like glucose and contributes to the regulation 
of body temperature. Although there is a gradual decline in muscle mass associated with aging, 
a certain percentage of the population suffer from severe muscle mass and strength deterioration, 
classified as sarcopenia (5-13% for people aged 60-70 years old, 11-50% for those 80 or older). 
Sarcopenia is linked to increased morbidity and mortality rates in the elderly population, while 
annual healthcare costs related to sarcopenia total in the millions of dollars. Because the 
prevalence of sarcopenia is expected to increase as a larger percentage of the population 
transitions into old age, it becomes imperative to understand the mechanisms of aging and 
longevity so that more effective interventions can be taken against age-related muscle 
deterioration. Our laboratory has previously demonstrated that resveratrol, a known activator of 
the protein sirtuin 1 (SIRT1), was effective in enhancing human muscle adaptations to exercise 
in elderly populations. A rich body of literature has long supported the association of SIRT1 with 
longevity, but there are still gaps in our knowledge of how SIRT1 expression affects the 
functionality and performance of muscles in aging skeletal muscle. Furthermore, SIRT1 has been 
shown to be important in the function of muscle satellite cells—which are muscle stem cells that 
are responsible for the majority of muscle regeneration. However, there is little knowledge about 
how SIRT1 expression affects muscle regeneration and performance after injuries. To investigate 
the role of SIRT1 in the performance of aging and injured skeletal muscle, we have employed the 
use of several transgenic mouse models with differential expression of SIRT1. Using these 
 models, we performed a series of functional muscle tests, before and after cardiotoxin (CTX) 
induced muscle injuries, to identify and compare muscle aptitude and recovery capability. Skeletal 
muscle sections from each model were also taken to identify differences in muscle fiber size and 
type distribution. Additionally, both mitochondria and satellite cells were isolated from these 
models to assess whether SIRT1 expression contributed to differences in metabolic or 
regenerative capacities. We found that there was little functional difference between young wild-
type (YWT, aged 20-30 weeks) and aged (80+ weeks old) wild-type (WT-80), SIRT1 
overexpressor (OE-80), and SIRT1 muscle-knockout (MKO-80) mice in either force production or 
fatigability in the absence of intervention. Mice lacking SIRT1 expression in their satellite cells 
(SKO-80), however, did show a reduction in force production. Interestingly, both the OE-80 and 
MKO-80 mice showed significant (P < 0.05) increases for p53 expression and reduced fatigability 
after recovering from injury, with the SIRT1 overexpressor model showing some signs of muscle 
potentiation. MKO-80 mice showed a significant increase in satellite cell regeneration (P < 0.05) 
in vitro when analyzed with EdU, but no difference in proliferation when compared in vivo with 
BrdU, indicating that SIRT1 expression in adult skeletal muscle may be an early factor in limiting 
the proliferation of satellite cells. The mitochondrial and structural profiles of each model were 
found to have minimal differences. Overall, our data indicate that although SIRT1 expression in 
skeletal muscle does not seem to be necessary for normal muscle function after injury, it does 
exert some influence in muscle repair. Altering SIRT1 expression either positively or negatively in 
skeletal muscle improves muscle fatigability in injury-recovered muscles, indicating a potential 
regulatory role for SIRT1 in skeletal muscle, but not an essential requirement for its deacetylation 
activity. Interestingly, these alterations of SIRT1 expression in aged skeletal muscle also resulted 
in a significant increase of p53 expression, indicating a potential benefit for p53 expression to 
muscle recovery. SIRT1 expression in satellite cells was shown to be necessary to achieve 
normal contractile force, but did not affect fatigability in those muscle. Our work has indicated a 
complex role for SIRT1 in skeletal muscle regeneration. We have shown for the first time that 
 SIRT1 is required in satellite cells for proper function, but is not essential for muscles to recover 
their functionality after injury. We have also provided evidence for a potentially new target for 
muscle recovery, the protein p53, and new insights into the role of SIRT1 in muscle recovery.  
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Specific Aims 
Muscle function peaks for the average person by 30 years of age; afterwards, most people 
experience an average decline of up to 1% muscle mass per year—a loss that can be exacerbated 
in old age (~65 years old) to up to a 3% loss per year [1]. This age-related loss of muscle mass 
is generally referred to as sarcopenia. A clinical working definition was established in 2010 by the 
European Working Group on Sarcopenia in Older People to characterize sarcopenic individuals 
as those with low muscle mass coupled with low muscle strength, where muscle mass is two or 
more standard deviations below the mean average of healthy young adults (when matched for 
sex) [2]. The focus of researchers on sarcopenic muscle wasting has increased over the last 
decade as evidence has accumulated to establish the growing relevance of sarcopenia to overall 
health. Sarcopenia is viewed most prevalently in the context of personal mobility, with the 
resultant loss of balance, coordination, and stability from muscle wasting acting as both a direct 
(impairing muscle performance) and indirect (increasing the likelihood of fall-related injuries) 
cause of physical disability [3]. Furthermore, prolonged immobility resulting from an injury or 
surgery can compound age-related muscle loss, possibly leading to permanent disability [4]. Loss 
of mobility and independence may often result in the need for assisted care or extended hospital 
stays; therefore, it is not surprising that estimates have suggested healthcare expenditures related 
to sarcopenia had cost the United States $18.5 million in the year 2000 alone [5]. 
Beyond the detriment sarcopenia brings to independence and quality of life, the loss of 
mobility resulting from age-related muscle loss also reduces the likelihood the elderly can benefit 
from physical exercise. The American College of Sports Medicine promotes the paradigm that 
“Exercise is Medicine,” a sentiment that is echoed by research touting the benefits of exercise in 
treating and preventing chronic disease [6,7]. Routine exercise is correlated with a reduced risk 
of developing cancer [8] and is recommended by the American Heart Association to help prevent 
the development of cardiovascular disease [9]. Furthermore, physical exercise is also strongly 
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recommended for the prevention and treatment of type 2 diabetes [10], signifying the importance 
of muscle not only for mobility and exercise, but also as a major metabolic regulator. Skeletal 
muscle mass accounts for roughly 20% of the body’s resting metabolism and acts to regulate 
body heat and multiple metabolites like glucose, amino acids, and fatty acids [11]. Therefore, the 
cumulative effect of muscle loss with aging has far-reaching consequences for overall health, 
necessitating further characterization of the processes that underlie both sarcopenia and aging in 
general.  
Interestingly, sarcopenia selectively causes marked atrophy and weakness in type II 
muscle fibers; whereas type I, oxidative fibers are largely spared from the most negative effects 
of aging [12]. It is largely unknown why type I fibers are selectively preserved in sarcopenia. The 
protein sirtuin 1 (SIRT1) is an NAD+-dependent deacetylase known to promote longevity in 
several model organisms [13] and is well characterized as metabolic regulator highly associated 
with oxidative, type I muscle fibers [14]. The long-term goal of our work was to identify the 
physiological and functional relevance of SIRT1 to skeletal muscle function in aging and muscle 
recovery and to determine whether SIRT1 could function as a suitable target for interventions 
against age-related muscle deterioration. The central hypothesis of this dissertation was that 
the preservation of type I fibers in aging was related to the high expression of SIRT1 in those 
fibers and that a loss of SIRT1 would exacerbate the fatigability and attenuate force output in 
muscle of aged mice. Furthermore, we hypothesized that increasing SIRT1 would improve muscle 
functionality by improving mitochondrial health in skeletal muscle—through increasing the 
abundance of mitochondria and the enzymatic activity of mitochondrial respiratory complexes—
and by increasing muscle satellite cell abundance. We tested our hypothesis by investigating 
the following specific aims: (1) elucidate the role of SIRT1 in regulating muscle function and 
fatigue resistance in regenerating skeletal muscle of aged mice, (2) determine the role of SIRT1 
in regulating mitochondrial biogenesis and function in regenerating/aging skeletal muscle, and (3) 
determine if SIRT1 activation can improve proliferation in satellite cells in aging mice. 
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To address Specific Aim 1, we utilized 5 mouse models: YWT (young wild-type, aged 20-
30 weeks); WT-80 (wild-type mice, aged 80+ weeks); OE-80 (overexpressor mice, aged 80+ 
weeks), MKO-80 (muscle knockouts of SIRT1, aged 80+ weeks); and SKO-80 (satellite cell 
knockouts of SIRT1, aged 80+ weeks), all of which shared a common C57BL/6J background. 
These models were functionally compared via their skeletal muscle force generation and 
fatigability, factors which were induced by electrical stimulation of the hindlimbs. Our working 
hypothesis was that the loss of SIRT1 would exacerbate skeletal muscle fatigability and reduce 
muscle force after injury, while overexpression of SIRT1 would protect against these effects.  
To address Specific Aim 2, we isolated mitochondria from skeletal muscles of our aged, 
transgenic mouse models and compared the number and size of mitochondria, as well as the 
mitochondrial membrane potential and complex activity. Our working hypothesis was that the loss 
of SIRT1 in the skeletal muscle knockout and satellite cell knockouts models of aged mice would 
reduce mitochondrial activity and increase mitochondrial dysfunction in mature skeletal muscle.  
To address Specific Aim 3, we induced muscular injury in our mice through the 
administration of cardiotoxin (CTX) isolated from the Mozambique spitting cobra (Naja 
mossambica). We then administered 5-bromo-2’-deoxyuridine (BrdU) through drinking water with 
ad libitum access and allowed the mice to recover for 3 weeks. After the mice recovered from 
their injuries, we evaluated their muscle performances and the number of BrdU positive nuclei as 
a measurement of proliferation. Additionally, we isolated satellite cells from each model and 
labeled the cells with 5-ethynyl-2’-deoxyuridine (EdU). EdU labeled cells were then allowed to 
proliferate and were subsequently quantified as a measurement of satellite cell proliferation. Our 
working hypothesis was that overexpression of SIRT1 would improve muscle satellite cell-
mediated skeletal muscle regeneration and muscle function after injury by increasing the 
proliferation of satellite cells.  
The data generated from this study was significant because it expanded upon previous 
work, which mainly characterized structural, biochemical, or metabolic differences in skeletal 
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muscle associated with altered SIRT1 expression, and did not investigate the translational effects 
these differences had on actual muscle performance. Furthermore, our findings were novel in that 
they highlighted a potentially important association between the expression of SIRT1 and p53 
during skeletal muscle repair, enhancing our understanding of the repair process of skeletal 
muscle in aging mice. 
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Literature Review 
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1.1 Aging Skeletal Muscle: Sarcopenia 
In a letter dated August 4th, 1836, Charles Darwin wrote to his sister, “…I shall act, as I 
now think—that a man who dares to waste one hour of time has not discovered the value of life.” 
This small sentiment of Darwin unintentionally illustrates the underlying nature of longevity 
research: time is a fundamentally valuable, but limited resource. Scientific study and modern 
medicine have long benefitted human health; the Center of Disease Control (CDC) FastStats, for 
example, detail a progressive increase in life expectancy (at birth) for the United States from 1900 
(47.3 years) to 2015 (78.7 years) [1]. Modern science, however, credits Dr. Nathan W. Shock as 
the “father of gerontology,” due in part to his landmark, longitudinal study detailing the age-related 
changes in physiological function across the heart, kidneys, lungs, nerves, and brain [2]. His study 
was the first to markedly observe differential rates of functional decline between individuals and 
spurred forward new investigations into the process of aging. The intricacies of aging have been 
examined to mechanistic levels across a vast spectrum of models and tissues, including skeletal 
muscle. Currently, the majority of investigations into aging skeletal muscle are framed within the 
context of sarcopenia.  
The term ‘sarcopenia’—derived from the Greek sarx, meaning ‘flesh,’ and penia, meaning 
‘poverty,’—was established by Dr. Irwin H. Rosenberg in an effort to draw serious attention to the 
dramatic decrease in lean muscle mass observed with aging [3]. Although a cursory internet 
search generally defines sarcopenia as the loss of muscle mass with aging, more recent literature 
has attempted to define and refine the differences between general and clinical sarcopenia. The 
first attempt at a clinical definition came from a study investigating elderly Hispanic and non-
Hispanic white subjects living in New Mexico. The investigators defined the cutoff values for 
sarcopenia as two standard deviations (SD) below the mean muscle mass relative to reference 
data for sex-matched subjects 18-40 years old and quantified according to the Appendicular 
Skeletal Muscle Mass (ASM) index to account for height differences among subjects [4]. In this 
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initial study, balance abnormalities, histories of bone fractures, and falling accidents were 
associated with sarcopenia [4]. Furthermore, sarcopenia showed significant correlation with both 
age and obesity, independent of biological sex. This finding would lead to another investigation, 
establishing the existence of sarcopenic obesity (defined in that particular study as sarcopenia 
coupled with body fat greater than the 60th percentile of the study) [5]. Sarcopenic obese patients 
were identified as being significantly more likely to be male and were 2.5 times as likely to report 
functional decline according to the Instrumental Activities of Daily Living (IADL) index. Importantly, 
both obese and non-obese subjects that reported functional IADL drops were reported to have 
over a 20% increase in death rates relative to the elderly who did not show IADL drops. However, 
a growing accrual of conflicting reports initially disputed these claims by providing strong evidence 
that low relative muscle mass alone did not contribute to increased rates of disability or death 
[6,7]. Notably, analyses based on the Health, Aging, and Body Composition (HABC) longitudinal 
study following 3,075 men and women, ages 70-79, indicated that the decline of lean body mass 
alone could not account for an increase in persistent lower extremity limitation, when normalized 
only to height [8]. To the contrary, subjects defined as sarcopenic by the ASM in some cases 
showed no decline in lower extremity performance, despite their relatively low muscle mass, 
whereas including obesity as a factor allowed for better prediction of functionality loss for subjects 
classified as sarcopenic. Furthermore, a later evaluation of the HABC study also showed evidence 
that an age-associated decline of muscle strength, evaluated as the torque generated by the mid-
thigh muscle of elderly subjects, occurred independently from the loss of mass [9]. Loss of muscle 
strength was up to 5 times greater when adjusted to the relative loss of muscle CSA, and could 
occur in subjects that lost weight, in weight-stable subjects, and even in subjects that showed 
small increases in muscle CSA. The growing body of work reporting similarly conflicting results 
began to illustrate the need for a better definition of sarcopenia [10]. 
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In 2011, the European Working Group on Sarcopenia in Older People (EWGSOP) 
convened to create a consensus on the working definition of sarcopenia [6]. EWGSOP 
recommended that beyond the criterion of low muscle mass (defined by 2 SD below mean muscle 
mass of sex-matched, healthy young adults), subjects should present at least one of two criteria: 
low muscle strength (handgrip: < 30 kg men/ 20 kg women) or low physical performance (gait on 
6m course: < 1 m/s men, < 1.175 m/s women).These working definitions set a baseline for 
consensus in scientific research that aimed to reduce the variability seen in the prevalence of 
sarcopenia.  
Despite the lack of a universal adoption of the EWGSOP standard, meta-analysis of 
previously published literature—recontextualized with these standards—has identified a clear link 
with sarcopenia to mortality and functional decline [11]. Although clear epidemiological studies 
are lacking for other commonly reported outcomes of sarcopenia—including falls, fractures, and 
increased frequency and length of hospitalization—evidence does suggest that injuries can 
worsen the sarcopenic state. The most commonly studied injuries related to sarcopenia are hip 
fractures, which are cited as the most frequently occurring fall-related injuries, outside of 
superficial injuries, to persons aged ≥ 75 years old [12]. Such falls may continue to harm elderly 
patients during hospitalization, as extended bouts of muscle disuse and/or immobility have long 
been attributed to reductions in skeletal muscle and bone mass [13–15]. One cross-sectional 
study reported that at least 75% of elderly men and 50% of elderly women (> 70 years) 
hospitalized with hip fractures were attributed with sarcopenia—rates generally over 20% more 
than age-matched patients without hip fractures [16]. Longitudinal studies have also shown that 
hospitalized geriatrics with sarcopenia are significantly more likely to experience mortality in as 
few as 2 years post-hospitalization [17,18]. Sarcopenic geriatrics who do survive are faced with 
the grim aspect of rising healthcare costs. A 2004 study estimated that spending in 2000 for 
sarcopenia in the United States likely amounted to $18.5 billion in healthcare costs, just in 
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consideration of spending related to disability services, including hospitalization, rehabilitation, or 
at-home health services [19].  
1.2 Selective Atrophy of Type II Fibers with Sarcopenia  
Interestingly, sarcopenic muscle wasting does not appear to affect skeletal muscles 
homogenously. Skeletal muscle across mammals consists of heterogenous populations of 
myofibers, most easily differentiated by their contractile and metabolic properties [20]. Contraction 
properties are dependent on the expression of myosin heavy chain isoforms, which have 
differential rates of ATP hydrolysis—determinants of the twitch characteristics (i.e. whether the 
fiber is a fast-twitch or slow-twitch fiber). Type II fibers are pale muscle fibers reliant on glycolysis 
for their metabolism, are capable of undergoing marked hypertrophy, and are characterized by 
fast-twitch contractions. In contrast, type I fibers are a red, due to their rich myoglobin content, 
which is used to sequester oxygen. This oxygen is necessary for respiration, as these fibers are 
reliant on oxidative phosphorylation for their energy needs. Furthermore, type I fibers are 
characterized as slow-twitch fibers and undergo ATP hydrolysis at a slower, but more continuous 
rate.  
Characterization of skeletal muscle fibers from human subjects aged 65-86 years old has 
shown that type II fibers are smaller in their mean individual CSA and cover about 13% less total 
CSA than do type I fibers [21]. The smaller occupied area also correlates with fewer muscle 
satellite cells (MSCs) per fiber, totaling to about 0.9% fewer MSCs overall. In a separate study 
comparing the characteristics of the vastus lateralis muscle in young (24-26 years old) and elderly 
(70-72 years old) men, type II fibers were shown to decrease in in CSA up to 29% in the elderly, 
relative to a mean decline of 20% across all fiber types [22]. Furthermore, the quantity of type II 
fibers decreased by about 10%, without significant change in type I fiber quantity. Overall, these 
reductions were shown to generate a 14% reduction of CSA in aged quadricep muscles relative 
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to the control young men. This selective atrophy of type II fibers is also exacerbated with 
prolonged immobility resulting from hip fractures in elderly female patients [23].  
1.3 Loss of Muscle Satellite Cells with Type II Fibers 
Associated with the loss of type II fibers is a reduction of satellite cells and myonuclei. 
Muscle satellite cells (MSCs) are mononucleated stem cells that derive their name from their 
physiological location around myofibers, situated between the fiber’s plasma membrane and the 
muscle basal lamina [24]. The position of these muscle stem cells is critical to their function in 
vivo: damage to the host skeletal muscle activates MSCs to initiate muscle repair [25,26]. Vital to 
MSCs is the paired box 7 (Pax7) transcription factor. Mice models knocked out for Pax7 
completely lack MSC populations [27] and tamoxifen-induced inhibition of Pax7 in adult satellite 
cells severely reduces muscle repair and leads to marked muscular atrophy [28,29].  
Importantly, satellite cells contribute to muscle repair through a mechanism of asymmetric 
division, a process that maintains two distinct fates for MSCs: proliferation or differentiation [30]. 
Generally, Pax7-expressing MSCs operate in a state of quiescence with little to no activity beyond 
basal metabolism [24]. Upon activation by injury, MSCs will upregulate the expression of 
myogenic differentiation factors, which drive the asymmetric division: co-expression of Pax7 and 
MyoD (myogenic differentiation 1) commit satellite cell populations to proliferation, whereas 
expression of MyoD and downregulation of Pax7 commit these sells to differentiation [31]. 
Importantly, the pool of satellite cells available for muscle repair declines in association with aging 
[32]. Associated with the decline of satellite cell number is a loss of regenerative capacity for 
muscle repair, although this decline occurs without an associated loss of differentiation potential, 
indicating that age-related dysfunction in regeneration is associated with satellite cell abundance 
and/or proliferative capacity [33]. In association with the decline of CSA/mass linked to selective 
type II fiber atrophy, cross-sectional studies in geriatrics (>70 years of age) have also shown that 
MSC populations are specifically lower in type II muscle fibers relative to type I fibers [21]. 
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Furthermore, the decline in overall abundance of MSCs in type II fibers appears to be specific to 
those fiber types [34,35]. These data suggest that a decline in satellite cell population likely 
stemming from reduced proliferation contributes to the loss of muscle mass and function 
characteristic of sarcopenia. 
1.4 Oxidative Stress Accompanies Mitochondrial Aging in Sarcopenia 
In addition to loss of satellite cells and regenerative capacity, sarcopenic muscles have 
also been reported to express hallmarks of mitochondrial dysfunction [36,37]. Aging mitochondria 
have been associated with the dysregulation of mitochondrial fission and fusion proteins in rodent 
models, coinciding with abnormal mitochondrial structures—including extensive fragmentation 
[38]. Notably, aged rodents have been shown to have reduced levels of mitochondrial fusion 
proteins Mfn1/Mfn2 compared to young controls. A similar dysregulation has been noted in rodent 
muscles undergoing 7 days of disuse, wherein the expression of the fission proteins Mfn2 and 
Opa1 were decreased relative to rodents whose dorsiflexor muscles were activated by stimulation 
over a period of 7 days [39]. The accumulation of fragmented mitochondria in aging tissue have 
been attributed to reduced clearance of damaged mitochondria by impaired mitophagy. 
Furthermore, a recent study has linked the CRISPR/Cas9-mediated knockout of the RNA-binding 
protein Pumilio2 (Pum2) to improved mitophagy, to mitochondrial house-keeping through the 
regulation of pathway-specific proteins downstream of MFF (mitochondrial fusion factor), and to 
increased lifespan in C. elegans [40]. Mitochondrial fission proteins and healthy mitophagy have 
been shown to accompany the removal of fragmented mitochondria and are stimulated by mild 
oxidative stress [41]. Although mild oxidative stress produced by mitochondrial metabolism does 
stimulate the expression of protective antioxidants through reactive oxygen species (ROS) 
signaling [42], highly elevated levels of ROS have been associated with mitochondrial dysfunction 
and oxidative damage to cellular structures [43].  
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Sarcopenic skeletal muscles show increased rates of dysfunction relative to muscle tissue 
from non-sarcopenic subjects, including elevated levels of reactive oxygen species (ROS) and 
oxidative damage. Dysregulation of electron transport chain complexes, like cytochrome-c 
oxidase (COX), occurs more prevalently in sarcopenic muscle [44], and is a major contributor of 
ROS production in dysregulated mitochondrial metabolism associated with aging [45]. For 
example, the superoxide reactive species is produced by NADPH oxidases during oxidative 
phosphorylation [42]. Unless quenched by protective enzymes—in this case, the family of 
superoxide dismutase (SOD) proteins—superoxide can react to form more free radicals, which 
can rapidly accumulate and cause widespread oxidative damage to the cellular environment 
through radical chain reactions. As such, tissues heavily reliant on oxidative phosphorylation 
transcribe elevated levels of antioxidants and ROS scavengers—such as the glutathione 
peroxidase family of enzymes responsible for removal of H2O2—to scavenge free radicals and 
reduce the amount of oxidative damage done to cellular proteins, membranes, and DNA [46]. 
Important to the context of sarcopenia, elevated oxidative stress levels have frequently 
been associated with age-related dysfunction in tissues, particularly in skeletal muscle. Previous 
work from our lab has shown that subcutaneously implanted allopurinol inhibits xanthine oxidase 
(XO), a source of ROS production during exhaustive exercise and significantly blunts ROS 
production in the isolated mitochondria of aged mice [47]. Furthermore, this reduction of 
mitochondrial ROS was accompanied by an attenuation of force production during electrically-
stimulated isometric muscle contractions in aged rodents.  
Support for the beneficial effects of reducing oxidative stress in promoting muscle function 
have also been evidenced by the application of the dietary antioxidants (vitamins E & C) [48] and 
green tea extract (GTE), whose active ingredient is the polyphenol epigallocatechin-3-gallate 
(EGCG) [49]. Interestingly, though both models attenuated oxidative damage to the muscles, the 
profiles of protection differed between dietary supplements. Oxidative stress was shown to be 
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attenuated in GTE-treated mice through the reduction of protein carbonyls and prostaglandins—
markers of oxidative stress—and attenuated muscle wasting from disuse. These mice, however, 
did not show changes in SOD levels, which accompanied oxidative stress changes in both the 
previous XO-inhibited mice [47] and vitamin E&C treated mice [48]. Vitamin-fed mice also 
experienced an increase in muscle work after treatment in aged mice. These data suggest that 
oxidative stress negatively effects muscle throughout widespread pathways. 
1.5 SIRT1 Protein Protects against Cell Death under Stress 
 Aside from directly affecting muscle function, oxidative stress can activate pro-apoptotic 
pathways and induce cellular death. One pro-apoptotic protein shown to be activated by oxidative 
stress and elevated ROS abundance is the tumor suppressor p53. The p53 protein is known to 
regulate a wide array of cellular processes, most notably cell cycle arrest and the induction of 
apoptosis. Upregulation of p53 is a multifaceted process dependent on multiple stress-response 
pathways, but can be initiated by ROS through the initiation of the DNA-damage repair pathway 
[50]. Although the elevation of ROS levels alone is not strongly linked to increased cell mortality, 
elevated ROS levels have been linked to increased cell mortality when co-induced with p53 in 
H1299 lung carcinoma cells [51]. Interestingly, elevated p53 abundance is linked to aging through 
the DNA-repair pathway, as the accrual of DNA damage is shown to correlate with age across 
multiple tissue types in human models [52]. In skeletal muscle, p53 abundance is also shown to 
be elevated in the muscles of C57BL/6-background murine models undergoing prolonged 
immobilization, linking p53 abundance to disuse-induced muscle atrophy. Indeed, the transgenic 
knockdown of p53 in these immobilized mouse models significantly attenuates muscle atrophy 
[53]. 
 One protein that is associated with both oxidative fibers and with inhibiting p53-induced 
cellular death is sirtuin 1 (SIRT1) (Fig 1-2). SIRT1 is an NAD+-dependent histone deacetylase. 
Aside from histone deacetylation, SIRT1 has also been shown to directly deacetylate non-histone 
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proteins to promote or inhibit their function; indeed, one of the first non-histone proteins shown to 
be targeted for direct deacetylation by SIRT1 is p53 [54]. Targeted knockdown of SIRT1 in yeast 
has been shown to increase the acetylation of p53 and reduce yeast lifespan, whereas 
overexpression of SIRT1 decreases p53 acetylation and improves lifespan. Conversely to 
protecting cellular integrity under oxidative stress, the transgenic knockdown of SIRT1 in leukemia 
cells has been established as a method to promote p53’s downstream apoptotic pathways in 
order to inhibit chronic myelogenous leukemia tumorigenesis [55].  
 The protective effects of SIRT1 against muscle atrophy have also been shown through its 
inhibition of the forehead box O (FOXO) family of proteins. FOXO proteins are a family of 
transcription factors known to promote apoptosis through the transcription of FasL, the ligand for 
the Fas-dependent cell-death pathway, and through activation of the pro-apoptotic Bim (Bcl2-like 
protein 11), a member of the Bcl-2 (B-cell lymphoma 2) family of proteins [56]. The Bcl-2 family 
of proteins inhibit apoptosis by negative regulation of pro-apoptotic Bax and Bak proteins [57]. 
Subsequent to the loss of Bcl-2 inhibition, Bax or Bak will generate an apoptotic pore in the 
mitochondrial outer membrane [58]. This apoptotic pore facilitates the leak of inner mitochondrial 
substances; one such substance is cytochrome-c, a heme protein important to cytochrome c 
oxidase (complex IV of the mitochondrial electron transport chain). Immediately after release, 
cytochrome-c will bind to the apoptotic protease activating factor 1 (Apaf1) protein, initiating the 
formation of the apoptosome and initiating cellular destruction through the proteolytic caspase 
cascade [59]. Therefore, inhibition of FOXO proteins by SIRT1 promotes cellular survival by 
inhibiting apoptosis. Co-immunoprecipitation of FOXO3 and SIRT1 at endogenous levels in 293T 
HEK (human embryonic kidney) cells has indicated a direct binding of the two proteins, while the 
isolation and purification of acetylated FOXO3 was shown to be deacetylated by recombinant 
SIRT1 in vitro, and only in the presence of NAD+ [60].  
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Of particular interest to the context of sarcopenic muscle wasting, SIRT1 levels in type II 
muscle fibers have been reported to drop significantly after 48 hours of fasting, coinciding with 
the increased abundance of the atrophy-associated ubiquitin ligases, atrogin1 and Murf1, and 
increased muscle atrophy [61]. Electroporation of these fasted muscles to increase SIRT1 
expression rescues and protects these muscle fibers from atrophy, with the CSA of electroporated 
fibers out-sizing non-treated fibers by over 48%.  
1.6 SIRT1 Protein Association with Type I Fibers 
 The cumulative protective effects SIRT1 exhibits in preventing muscle wasting from 
atrophy and apoptosis, especially SIRT1’s attenuation of the significant atrophy in type I fibers 
undergoing long-term caloric deficit, suggest the possibility of a role for SIRT1 in preserving 
muscles fiber with aging, particularly type I fibers. The rationale underlying this possible role come 
from the strong association of SIRT1 with mitochondrial metabolism (as high mitochondrial 
abundance is characteristic of type I fibers). As mentioned previously, NAD+ (nicotinamide 
adenine dinucleotide) is required for the functional activity of the SIRT1 protein [62,63]. NAD can 
exist in either the oxidized (NAD+) or reduced (NADH) form, with the reduced NADH acting as an 
electron carrier to NADH dehydrogenase, complex I of the mitochondrial electron transport chain 
in oxidative metabolism [64]. During low-energy cellular states, such as after prolonged muscle 
contraction or during caloric restriction, the ratio of NAD+/NADH increases, promoting SIRT1 
activity [65,66].  
 Beyond its dependence on a key substrate of mitochondrial respiration for activation, 
SIRT1 is also a known regulator of the peroxisome proliferator-activated receptor γ coactivator-
1α, PGC-1α [67]. Co-immunoprecipitation assays of liver extracts were used to identify direct 
protein-protein interaction between SIRT1 and PGC-1α, while an in vitro deacetylase assay 
provided evidence that SIRT1 deacetylated PGC-1α upon the addition of NAD+ as a substrate. 
Previous to this study, PGC-1α induction had been reported as inducing gluconeogenesis [68] 
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and fatty acid oxidation [69,70] in the liver, a metabolic shift that closely resembled the hepatic 
response to short-term fasting [71]. Indeed, caloric restriction activates SIRT1 activity through 
alterations in the NAD+/NADH ratio [72]; furthermore, overexpression of the SIRT1 protein by a 
transgenic knock-in of SIRT1 through the cre-loxP system, driven by the β-actin promoter, was 
reported to produce a calorically restricted phenotype in the mouse model [73]. This mouse model 
was shown to have significantly less bodyweight, fewer circulating free fatty acids and cholesterol, 
and improved glucose homeostasis, despite taking in more calories than control mice 
standardized to body weight—hallmarks of increased adipose/mitochondrial metabolism. Recent 
evidence has also indicated that loss of SIRT1 abundance and activity in muscle satellite cells is 
a key step during the metabolic shift of MSCs from oxidative to glycolytic metabolism, a process 
necessary for MSC differentiation [74]. 
 In addition to promoting an oxidative-like metabolic profile, SIRT1 abundance may be 
related to fiber type distribution in mouse models. Gain-of-function models of SIRT1 activity, with 
transgenic overexpression induced through the muscle creatine-kinase (MCK) promoter, have 
been reported to induce fiber type switching in mouse models of Duchenne’s muscular dystrophy 
[75]. However, SIRT1-knockout mice in the same study, also driven by the MCK promoter, did 
not show a decrease in type I fibers. In a Sprague Dawley rat models of aging, groups of 3 month 
old and 12 month old rats that underwent swimming training for 40 min/day (5 days/week, 4-12 
weeks) showed increased abundance of SIRT1 in the predominantly-type I soleus muscles in 
exercised rats relative to age-matched sedentary controls, though no difference in SIRT1 
abundance was detected between exercised and sedentary groups in isolated gastrocnemius 
(predominantly type II) muscles [76]. Similar results have also been reported for male Wistar rats 
subject to endurance exercise interventions of low (20 m/min, 90 min/day) and high (30 m/min, 
60 min/day) intensity [77]. Both low and high intensity exercise increased SIRT1 abundance in 
soleus muscle of trained rats relative to untrained controls, but only high intensity increased SIRT1 
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expression in the predominantly type II plantaris muscle relative to untrained control rats. 
Additionally, SIRT1 abundance was shown to be significantly greater in the soleus muscle of 
these rats when compared to the abundance in plantaris muscles for basal and trained muscles.  
 Despite the oxidative/caloric restriction phenotype seemingly promoted by SIRT1, some 
models of SIRT1 overexpression in rodents have been reported to show no benefits to glucose 
or fatty acid metabolism. MCK-driven, SIRT1 muscle overexpressor mice fed either control or 
high-fat diets did not report increases in glucose clearance and fatty acid metabolism, metabolic 
profiles associated with the caloric restriction phenotype [78]. Similar effects were reported in a 
male Wistar rat model of SIRT1 overexpression, with SIRT1 abundance increased in vivo through 
muscle electroporation of an active or inactive copy of SIRT1 into the tibialis cranialis muscle [79]. 
Overexpression of SIRT1 over a one-week span did not improve glucose tolerance, nor did it 
protect against insulin resistance—metabolically protective effects observed in other caloric 
restriction models. One explanation is that the increased abundance of SIRT1 does not always 
equate to an increase in the enzymatic activity of SIRT1. However, several activators of SIRT1 
have been shown to more consistently induce protective effects against aging.  
1.7 SIRT1 Activators Attenuate Effects of Aging 
1.71 Caloric Restriction Improves Lifespan 
Research on caloric restriction (CR) has been ongoing since the initial report in 1935 that reducing 
caloric intake could extend the lifespan of rats relative to controls with ad libitum access to food 
[80]. However, modern research investigating SIRT1’s role in linking longevity to CR began with 
the discovery that overexpression of the yeast protein Sir2 (silent information regulator 2), could 
increase the lifespan of yeast by up to 50% [81]. Two follow-up studies in Saccharomyces 
cerevisiae (S. cerevisiae) and in the Caenorhabditis elegans (C. elegans) further established two 
important facts: (1) caloric restriction activated Sir2 activity in yeast by reducing the availability of 
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NADH, which acts as a competitive inhibitor to NAD+, to induce Sir2’s activity [72], and (2) a family 
of proteins with high homology to Sir2 were active in C. elegans, and that overexpression of the 
protein with the highest homology to Sir2, Sir2.1 (31% identity to yeast Sir2), could also extend 
lifespan of C. elegans by approximately 50% [66]. These proteins with high homology to Sir2 
eventually became known as the Sir2-like, and later sirtuin (sir- “two”-in), family of proteins. These 
investigations laid the groundwork for future studies by establishing solid evidence that CR could 
activate SIRT1, and that organisms with greater complexity could also benefit from improved 
longevity via the overexpression of their respective Sir2 homologues. 
  More complex model organisms have also been shown to benefit from longer lifespan 
through caloric restriction. In most cases, these models limit calories by 25%-50%, though studies 
in mammals tend to restrict calories by around 30%. A Drosophila melanogaster (D. 
melanogaster) model of high (15% yeast, 15% sucrose, 2% agar) and low (5% yeast, 5% sucrose, 
5% agar) calorie sucrose cornmeal food (added in equal volume amounts) in transgenic flies 
expressing normal, elevated, or knocked out levels of Drosophila Sir2 (dSir2) [82]. CR coupled 
with dSir2 overexpression was shown to increase lifespan by 29% in females and approximately 
18% in male flies, though no extension of lifespan was detected for flies endogenous or reduced 
dSir2 abundance, nor in flies that had already lived long lifespans. Importantly, although these 
data indicated that dSir2 was important for mediating the extension of lifespan through caloric 
restriction, they did also reveal that CR alone does not guarantee an extension in lifespan for CR 
models. Despite these findings, CR alone has been able to induce lifespan extension in rodents 
by up to 50% and has improved the lifespan of primate models [83].  
One recent study investigating CR on grey mouse lemur populations reported that a 30% 
CR intervention administered at 3 years of age could extend the lifespan of these small primates 
by close to 50%, from a median of 6.4 years to a median of 9.4 years old, with 7 of the 19 CR-
intervention animals surviving up to 13 years (over double the median lifespan of the control 
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group) [84]. However, the increase in lifespan was also accompanied by the selective atrophy of 
grey matter in the brain temporal regions, hippocampus, and retrosplenial cortex. Although no 
cognitive impairment was detected in the CR lemur group, the changes in brain do illustrate that 
the effects of longevity in longer-lived organisms may not be wholly beneficial, and that the 
increasing complexity of the organism models may present unexpected outcomes. An important 
caveat of the grey mouse lemur study is that the lives of the oldest lemurs were extended by 7 
years past the medium control group, illustrating an important limitation to these studies: the 
commitment of extended periods of time to generate data. The impact of CR on primate longevity 
is still contested due to the resulting lack of a data owed to the longer life-span of these models. 
Rhesus monkeys, for example, can live for several decades, necessitating long commitments of 
time and severely slowing the generation of data. As such, current data on rhesus monkeys show 
conflicting results [85], with research from the University of Maryland and University of Wisconsin 
reporting a positive association of CR to survival, but the National Institute of Aging reporting no 
significant association.  
1.72 NAD Supplementation Improves Mitochondrial Health 
 Although CR activates SIRT1 by modulation of the cellular [NAD+]/[NADH] ratio, direct 
manipulation of [NAD+] can also be used to activate SIRT1. Recent studies have investigated the 
potential benefits of supplementing the NAD+ precursor, nicotinamide (NAM), to in vivo [86–88] 
and in vitro [89,90] models. Supplementation of NAM to primary human fibroblasts was shown to 
reduce mitochondrial mass and improve mitochondrial membrane potential ΔΨm [87]. These 
effects are accompanied by significant increases in the abundance of the autophagy-related 
proteins LC3 and ATG-12. Interestingly, the reduction of mitochondrial volume was also observed 
upon activation of SIRT1 through other activators (resveratrol, SRT1720), but these activators did 
not affect ΔΨm, suggesting the possibility of an alternate mechanism of regulation by NAD+ [88]. 
NAM supplementation was also reported to reduce the ROS content of primary human fibroblasts, 
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as detected by detection of the oxidant-sensing probe, DCFH-DA [86]. These data suggest that 
NAD treatment, through the activation of SIRT1, attenuate mitochondrial markers of aging by 
inducing mitophagy. Interestingly, NAM-treated fibroblasts were able to divide over 1.5-fold as 
many times as untreated fibroblasts, indicating an improvement to longevity. However, in C57BL/6 
mouse models of high and low-fat dietary intake, oral NAM supplementation improved locomotion 
functions, glucose tolerance, and reduced liver steatosis—indicating improved metabolic health—
but did not increase the lifespan of the mice [90]. 
 A similar profile of metabolic protection was observed in vivo in C57BL/6-backgroun mice 
chronically fed an alternate NAD+ precursor, nicotinamide riboside (NR) [91]. Interestingly, 
nicotinamide and nicotinamide riboside are both considered vitamin B3 variants, and both 
increase the concentration of intracellular NAD+. However, a key difference between these 
compounds is that NAM supplementation will begin to inhibit SIRT1 activity beyond a certain 
concentration threshold [86]. Secondly, NR has been shown to activate SIRT3 in addition to 
SIRT1, suggesting that NAD+ supplementation from NR promotes downstream effects in both the 
nuclear and mitochondrial compartments [91]. Evidence supporting beneficial effects in the 
mitochondrial compartment by NR comes from multiple studies of mitochondrial myopathy in 
Deletor [92] and Sco2 knockout [93] mouse models. These mitochondrial myopathies represent 
two separate mutations that lead to electron transport chain dysfunction, and share similar 
characteristics of mitochondrial myopathy (diminished abundance of mitochondrial COX and 
abnormal mitochondrial structure). In both cases, NR was reported to increase mitochondrial 
biogenesis in conjunction with an upregulation of the mitochondrial unfolded protein response 
(UPR). Stimulation of mitochondrial biogenesis was able to provide at least partial rescue for the 
downregulation of mitochondrial respiration, while mitochondrial structural rescue was attributed 
to increased protein integrity resulting from greater activation of the mitochondrial UPR. 
Interestingly, mitochondrial protection is conferred by both NR and NAM with similar downstream 
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effects, but different activating pathways. For example, abnormal mitochondrial structure is 
attenuated with treatment by both NAM and NR, but appears to be achieved more through 
mitophagy in NAM-supplemented models and through the mitochondrial UPR in NR-treated 
models. These differences illustrate the potential of SIRT1 to promote longevity through multiple 
pathways depending on the type of activation used to stimulate its activity. 
1.7.3 Resveratrol Protects Against Oxidative Stress 
 After the initial discovery of SIRT1’s pro-longevity effects, research began looking into in-
depth screenings of small-molecule libraries for potential activators of SIRT1. Of 25 small 
molecules found to enhance SIRT1 from a pool of over 20,000 molecules, a phenol naturally 
produced in plants, was found to be the most potent [94]. Supplementation of resveratrol was 
subsequently shown to increase the lifespan of yeast, mimicking the activation of SIRT1 through 
caloric restriction [95,96]. Based on reports that resveratrol conferred antioxidant properties that 
attenuated oxidative stress [97], our lab previously investigated the effects of dietary resveratrol 
on muscle function and age-related oxidative stress in aged and/or disuse models of rodent 
muscles. Both short (10 days) [98] and long-term (10 months) [99] supplementation of resveratrol 
in young and aged mouse models conferred protection against oxidative stress during isometric 
muscle contractions and in control mice, characterized by decreased muscular H2O2 levels and 
increased expression of antioxidant and ROS scavenger proteins, including glutathione 
peroxidase, catalase, and manganese-dependent superoxide dismutase. Despite protecting 
against oxidative damage, resveratrol did not protect against age-related [99] or disuse atrophy 
[96], though supplementation of resveratrol promoted the recovery of type II fiber CSA during 
recovery from disuse atrophy. Interestingly, in elderly human subjects (aged 65-80 years old), 
resveratrol supplementation coupled with 12 weeks of exercised increased maximum torque 
production during knee extension exercise and did improve mean muscle fiber CSA [100]. Of 
particular interest in this study was the increase in type II muscle fiber CSA and satellite cell 
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population. In conjunction with the improvement of type II fiber CSA after muscle disuse, these 
data suggest resveratrol activation of SIRT1 may improve muscle regenerative ability after 
damage by improving the pool of available satellite cells. 
1.8 SIRT1 as a Regulator of Muscle Satellite Cells 
 Although the role of SIRT1 in satellite cells is currently still emerging, increasing evidence 
suggests SIRT1 activity can influence satellite cell functionality. Short-term (12 weeks) CR has 
been shown to increase the quantity and proliferation in vivo of satellite cells from young (2 month 
old) and aged (18 months) C57BL/6-background mice [101]. Interestingly, this study also showed 
that donor satellite cells engrafted to mice positive for Duchene’s muscular dystrophy (mdx) 
showed a 4-fold greater engraftment of myofibers than satellite cells donated to recipient mdx 
mice fed a control diet. These findings reflect parabiosis studies, wherein the regenerative of 
MSCs from aged mouse donors is increased when transplanted into much younger hosts [102]. 
Taken together, these experiments suggest a high sensitivity for satellite cells to the state of their 
systemic environments. However, they also suggest that increased MSC proliferative capacity 
from CR could be promoted through external signaling, rather than through endogenous SIRT1 
activity.  
 Recent literature has reported that aged mice treated with NR show increased 
regenerative capacity after cardiotoxin (CTX) induced injury, coupled with increased abundance 
of Pax7-stained MSCs, and were more effective than MSCs from untreated mice in rescuing 
muscle repair in mdx mice [103]. This regenerative potential was lost with the knockout of SIRT1 
in satellite cells induced through the loxP system by a Pax7-cre promotor. These data appear to 
agree with a separate study that suggest SIRT1 expression acts to maintain quiescence through 
an oxidative, metabolic switch [74]. This study reports that SIRT1 deacetylase activity and NAD+ 
levels are elevated in quiescent satellite cells, which present an oxidative metabolic phenotype. 
Loss of SIRT1 expression in the muscle satellite cells via the same Pax7-cre driven knockout 
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model results in premature differentiation of satellite cells into muscle dysfunctional myofibers. 
Down regulation of SIRT1 is shown to occur before satellite cells shift to a glycolytic phenotype, 
indicating that oxidative metabolism and expression of SIRT1 are majorly important in maintaining 
quiescent satellite cell populations.  
 Finally, studies looking at autophagy in stem cells have shown consensus that reduced 
autophagy and mitophagy contribute to aging by permitting the accumulation of damaged proteins 
and organelles, leading to senescence [104]. MSCs from murine satellite cell knockout models of 
Atg7 (autophagy-related protein 7) showed reduced regenerative capability and prematurely 
expressed cyclin-dependent kinase inhibitors p16, p21, and p15, indicating early cell cycle arrest 
and stem cell senescence. Mitochondria in MSCs with dysfunctional mitophagy also showed 
altered mitochondria, which displayed reduced ΔΨm, and were accompanied by a marked 
increase in cellular ROS. In support of this data, another study has shown that the knockout out 
of SIRT1 (SIRT1-/-) activity in embryonic stem cells (ESC) reduces autophagic cell death under 
oxidative stress [105]. When stressed by H2O2-mediated ROS damage, SIRT1-/- ESCs showed 
reduced abundance of LC3 and decreased ΔΨm, similar hallmarks to the loss of autophagy in 
the MSC knockout model of Atg-7. The loss of autophagy-associated clearance in both muscle 
and embryonic stem cells with the loss of SIRT1 suggests a vital role for SIRT1 in MSCs.  
1.9 Conclusion 
Several factors support the idea that SIRT1’s longevity-promoting activity may also be 
induced to spare skeletal muscle from age-associated wasting. SIRT1 has been shown to directly 
bind and deacetylate both the pro-apoptotic proteins FOXO3 and p53. Interestingly, SIRT1 seems 
to act like a stopgap in muscle atrophy; SIRT1 is upregulated during mild caloric restriction and 
will inhibit FOXO3 to preserve muscle fibers, but eventually abundance of SIRT1 will diminish 
during prolonged starvation. Some evidence suggests SIRT1 plays a similar role with its inhibition 
of p53. Although p53 is pro-apoptotic, it has also recently been shown to upregulate DNA repair 
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machinery in cells. The pro-DNA repair effects of p53 are thought to be mediated through its ability 
to arrest the cell cycle—thereby granting DNA repair machinery the chance to repair DNA damage 
before promoting apoptosis. One explanation for SIRT1’s pro-longevity effects could be that it 
only partially inhibits p53 expression—stopping it just enough so that p53 can express it’s cell-
cycle arrest properties without inducing apoptosis. 
Interestingly, some studies have shown that SIRT1 leans more toward muscle repair than 
increasing satellite cell activity; specifically, the experiments involving resveratrol. Resveratrol has 
been shown to reduce oxidative damage and improve type II fibers’ CSA after reloading injury 
after muscle disuse and in humans after exercise training. In these studies, SIRT1 activation did 
not appear to protect muscle fibers from sarcopenic wasting. Instead, beneficial effects were seen 
after injury—somewhat supporting the idea that SIRT1 could be interacting with p53 to inhibit 
apoptosis and promote DNA repair. Notably, the studies that seemed to best promote satellite 
cell activity were those experiments that supplemented satellite cells with nicotinamide riboside, 
a strong activator of SIRT1 and a cellular marker of SIRT1. This is especially interesting given the 
data that Ryall et al. show with their satellite cell knockout model of SIRT1; that SIRT1 acts a 
metabolic regulator to maintain satellite cell quiescence and is downregulated prior to MSC 
activation, wherein the MSCs shift toward a glycolytic profile. Combined with the fact that satellites 
cells are highly sensitive to their environment, it is possible that NR supplementation is promoting 
a calorie-restriction like response across all tissues in vivo, thereby promoting SIRT1 and the 
oxidative metabolic profile both endogenously and exogenously in satellite cells and reinforcing 
the proliferative phenotype by keeping SIRT1 active in the MSCs.  
Regardless, the literature has made a strong case for SIRT1 to be a potential preserver of 
muscle with age: (1) it protects muscle fibers by inhibiting pro-apoptotic proteins, (2) it promotes 
mitochondrial biogenesis and mitophagy, processes that help attenuate mitochondrial aging, and 
(3) it has been shown to promote muscle repair after injury. 
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1.11 Figure Legends 
1.11.1 Figure 1 
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1.11.2 Figure 1. The biochemical function and cellular roles of SIRT1. (A) SIRT1 requires the 
substrate NAD+ to initiate deacetylation of lysine residues on target proteins. Upon binding of the 
target acetylated lysine group to the active site, SIRT1 catalyzes the hydrolytic cleavage of 
nicotinamide from the ADP-ribose base. During this process, the acetyl group is transferred to the 
ribose, forming 2’-O-acetyl-ADP-ribose. (B). The regulatory roles of SIRT1 in various cell types. 
Proteins in green are positively regulated by SIRT1 deacetylase activity, while proteins in red are 
negatively regulated.  
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The role of SIRT1 in skeletal muscle function and repair of older mice  
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2.1 Abstract 
Background. Sirtuin 1 (SIRT1), is a NAD+ sensitive deacetylase, that has been linked to 
longevity and has been suggested to confer beneficial effects that counter aging-associated 
deterioration. Muscle repair is dependent upon satellite cell function, which is reported to be 
reduced with aging; however, it is not known if this is linked to aging-suppression of SIRT1. This 
study tested the hypothesis that Sirtuin 1 (SIRT1) overexpression would increase the extent of 
muscle repair and muscle function in older mice.  
Methods. We examined satellite cell dependent repair in tibialis anterior, gastrocnemius, and 
soleus muscles of 13 young wild type mice (20-30 weeks) and 49 older (80+ weeks) mice that 
were controls (n=13), overexpressed SIRT1 in skeletal muscle (n=14), had a skeletal muscle 
SIRT1 knockout (n=12), or a satellite cell SIRT1 knockout (n=10). Acute muscle injury was 
induced by injection of cardiotoxin (CTX) and phosphate buffered saline was used as a vector 
control. Plantar flexor muscle force and fatigue were evaluated before or 21 days after CTX 
injection. Satellite cell proliferation and mitochondrial function were also evaluated in undamaged 
muscles.  
Results. Maximal muscle force was significantly lower in control muscles of older satellite cell 
knockout SIRT1 mice compared to young adult wild type (YWT) mice (P < 0.001). Mean 
contraction force at 40Hz stimulation was significantly greater after recovery from CTX injury in 
older mice that overexpressed muscle SIRT1 than age-matched SIRT1 knockout mice (P < 0.05). 
SIRT1 muscle knockout models (P < 0.05) had greater levels of p53 (P < 0.05 MKO, P < 0.001 
OE) in CTX-damaged tissues as compared to YWT CTX mice. SIRT1 overexpression with co-
expression of p53 was associated with increased fatigue resistance and increased force 
potentiation during repeated contractions as compared to wild-type or SIRT1 knockout models (P 
< 0.001). Muscle structure and mitochondrial function were not different between the groups, but 
proliferation of satellite cells was significantly greater in older mice with SIRT1 muscle knockout 
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(P < 0.05), but not older SIRT1 satellite cell knockout models, in vitro, although this effect was 
attenuated in vivo after 21 days of recovery. 
Conclusions. The data suggest skeletal muscle structure, function, and recovery after CTX-
induced injury are not significantly influenced by gain or loss of SIRT1 abundance alone in skeletal 
muscle; however, muscle function is impaired by ablation of SIRT1 in satellite cells. SIRT1 
appears to interact with p53 to improve muscle fatigue resistance after repair from muscle injury. 
Key words. Muscle atrophy; Skeletal muscle; Mitochondrial function; Satellite cells; Muscle force; 
Fatigue; Sarcopenia  
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2.2 Introduction 
Sarcopenia is the age-associated wasting of skeletal muscle which results in a loss of 
function [1]. Sarcopenia is accompanied by an increased risk for physical disabilities, fall-induced 
injuries, hospitalization/ institutionalization, and mortality [2], and it is exacerbated by obesity and 
metabolic disorders [3]. Mitochondria regulate muscle metabolism and mitochondrial dysfunction 
may play a role in sarcopenia [4]. Indeed, altered size and granularity have been observed in 
aging mitochondria [5,6], as well as in the mitochondria of subjects diagnosed with type 2 diabetes 
mellitus [7]. Concordantly, loss of mitochondrial function also occurs with aging and metabolic 
disorders [8], although some research suggests age-associated alterations in mitochondrial 
morphology are independent of lifespan [9]. It is interesting that the highly-oxidative type I muscle 
fiber, which has ~6% mitochondria volume [10] are generally thought to be  more resistant to 
sarcopenia-related muscle wasting than type II fibers [11] which have ~3% mitochondria volume 
density [10] . This might be due in part to a greater sensitivity of mitochondria in type II fibers to 
oxidative stress [12]. Preserving mitochondrial function is therefore a potential strategy for 
reducing sarcopenia in both fiber types. 
Sirtuin 1 (SIRT1) is a class III histone deacetylase [13] which is dependent on NADH to 
deacetylate its targets, making SIRT1 highly sensitive to metabolism. SIRT1 has been identified 
as a link between caloric restriction and longevity, with the overexpression of SIRT1 linked to 
increased lifespans for several organism models [14]. Furthermore, SIRT1 has also been shown 
to inhibit type I fiber atrophy during intermittent fasting, by deacetylating and inhibiting the 
transcription activity of FoxO1 and FoxO3 [15]. In addition, activating SIRT1 in muscle cells 
prevents the reduction in slower fiber type myosin heavy chain gene expression and prevents 
myotube wasting after glucose [16,17]. Importantly, SIRT1 has been identified as a regulator of 
protein peroxisome proliferator activated receptor gamma coactivator 1α (PGC1α) [18], which is 
a well-established regulator of mitochondrial biogenesis and glycolytic-to-oxidative fiber type 
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switching in mammalian skeletal muscle [19]. PGC-1α activation (i.e. deacetylation) occurs via 
AMPK activation of the deacetylase SIRT1 [20]. In fact, SIRT1 deacetylation of PGC-1α increased 
the expression of key glucose and lipid metabolism genes [21]. However, mitochondrial 
biogenesis in response to exercise is not impaired under SIRT1 knock out conditions and 
therefore SIRT1 deacetylation is thought to be via the control of acetyltransferase GCN5 [22]. 
Satellite cell dysfunction is another potential contributor to muscle loss in sarcopenia [23]. 
Satellite cells are mononucleated muscle stem cells that are responsible for the majority of muscle 
regeneration after injury [24,25]. Both the expression of SIRT1 and satellite cell populations have 
been shown to decrease with aging [26], inviting the possibility that increasing SIRT1 expression 
in older muscle models might act as a countermeasure to preserve muscle regenerative capacity 
and therefore improve muscle function after muscle injury in aging. Consistent with this idea, 
resistance exercise coupled with consuming resveratrol, a known activator of SIRT1, increased 
satellite cell proliferation and improved muscle fiber size and function in muscles of older humans 
to a greater extent than resistance exercise alone [27]. Furthermore, resveratrol also prevents 
cell death and increases differentiation of myotubes [28], whereas SIRT1 silencing evokes greater 
cell death and reduced differentiation [28]. In addition, SIRT1 was reported to maintain pools of 
satellite cells in the state of quiescence and SIRT1 loss-of-function was reported to invoke 
premature differentiation of muscle satellite cells [29]. Strengthening this argument, mild 
endurance exercise which increased SIRT1 was shown to rescue an aging-induced reduction in 
satellite cell numbers in rats [26,30]. However, other studies have shown differential patterns of 
SIRT1 expression according to age and tissue type [31], calling into question whether aging has 
universal effects on SIRT1. Thus, there is a need to further study the role of SIRT1 on 
mitochondrial function and satellite cell regulation of muscle repair in the context of muscle 
sarcopenia. 
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The purpose of this study was to investigate the role of SIRT1 in repairing muscle and 
restoring skeletal muscle function after acute muscle damage in older mice. Our hypothesis was 
that muscle overexpression of SIRT1 improves mitochondrial function and satellite cell activation, 
which improves muscle repair and function after acute injury, and in contrast, loss of SIRT1 in 
muscle or satellite cells of older mice reduces muscle repair and function after injury by 
suppressing satellite cell activation and reducing mitochondrial function. Contrary to our 
expectation, we found that muscle performance and the recovery of skeletal muscle after injury 
are largely unaffected by the abundance of SIRT1 in skeletal muscle, but ablation of SIRT1 in 
satellite cells impairs muscle repair and function. Nevertheless, SIRT1 abundance may work 
synergistically with p53 to reduce muscle fatigue after repair following muscle injury. 
2.3 Materials and Methods 
2.3.1 Research design.  
Two separate experiments were conducted on the five groups of mice.  Three to five mice 
were examined in each age group for each experimental comparison. In the first experiment the 
plantarflexor muscles (gastrocnemius and soleus muscles) received an acute cardiotoxin (CXT)-
induced injury. Plantarflexor force and fatigue were measured before and then again after 21 days 
of recovery following CTX injury to assess the degree that manipulation of SIRT1 protein 
abundance had on muscle function and recovery/repair from muscle damage.  In a separate 
study, the plantar flexor muscles and the dorsiflexor (tibialis anterior) muscles from mice in each 
of 5 groups received a CTX injection to induce acute muscle injury.  These muscles were used to 
assess the role of SIRT1 on muscle structure solely. As there was the potential that electrical 
stimulation to induce evoked contractions could affect muscle fiber size or structure acutely, we 
did not assess muscle function in this second study. 
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2.3.2 Animal Models.  
Five mouse models were examined. These included: (i) young wild-type (YWT) mice  that 
were 20-30 weeks of age, (ii) older wild-type mice  that were 80-120 weeks of age (WT-80),  (iii) 
SIRT1 overexpressor older mice that were 80-120 weeks of age (OE-80), (iv) SIRT1 older adult 
skeletal-muscle knockout mice that were 80-120 weeks of age (MKO-80), and  (v) SIRT1 satellite 
cell knockout mice that were 80-120 weeks of age (SKO-80). As ~50% of the animals died before 
they were 120 weeks of age, we chose to include older animals that were 80 weeks of age in our 
oldest group because, this is at a point where muscle signaling changes and muscle atrophy and 
function begins to deteriorate [32,33]. While these animals could not yet be considered to be old, 
this group had mice that ranged in age from 80-120 weeks, and the oldest animals in this group 
would be considered old. Therefore, we have chosen to describe this combined group as “older”. 
All wild-type mice were generated from C57BL/6J background mice purchased from Jackson 
Laboratories, USA. MKO-80 and SKO-80 mice were generated using the cre-lox system by 
crossing B6;129-Sirt1tm1Ygu/J mice containing loxP sites directing the removal of exon 4 of SIRT1 
with MCK-cre expressing B6.FVB (129S4)-Tg(Ckmm-cre)5Khn/J and Pax7-cre expressing 
Pax7tm1(cre)Mrc/J mice, respectively. Mice that overexpressed SIRT1 were generated from B6.Cg-
Tg(SIRT1)ASrn/J mice containing a wild-type mouse SIRT1 gene promoted by an endogenous 
BAC transgene.   
2.3.3 CTX-induced acute muscle injury.  
Acute muscle injury was induced by injecting the gastrocnemius, soleus, and tibialis 
anterior (TA) muscles with 10 μM cardiotoxin (CTX; Naja mossambica; Sigma, St. Louis MO, 
USA) [34] in 150 μL of phosphate-buffered saline (PBS). The contralateral limb was injected with 
150 μL of PBS as a vehicle control. Cage control recovery occurred for 21 days post-injection. 
During recovery, mice were given water containing 0.8mg/mL 5-bromo-2’-deoxyuridine (BrdU)  
(MP Biomedicals)  to identify satellite cells that achieved DNA synthesis over the recovery period 
39 
 
as previously used in our lab [24]. Post-recovery, the experimental groups were euthanized by 
myocardial extraction under heavy anesthesia. The muscles were then immediately collected and 
frozen in 2-methylbutane (ThermoFisher Scientific, Pittsburgh PA, USA) chilled by liquid nitrogen. 
Frozen tissue sections were mounted on corkboard with Tissue Tek O.C.T. compound 
(ThermoFisher Scientific, Pittsburgh PA, USA). 
2.3.4 BrdU Immunohistochemistry.  
Frozen tissue sections of control and post-CTX injured muscles were obtained with a Leica 
model CM3050S cryostat and the tissue was mounted on charged glass slides (ThermoFisher 
Scientific, Pittsburgh PA, USA). The frequency of muscle nuclei that were BrdU positive were 
measured as previously described by our lab   . Briefly, the slides were fixed at room temperature 
with 1:1 methanol:acetone (ThermoFisher Scientific, Pittsburgh PA, USA) and then permeabilized 
with phosphate buffered saline in 0.4% Triton X-100. Slides were then washed with PBS and 
allowed to incubate in 2M hydrochloric acid (ThermoFisher Scientific, Pittsburgh PA, USA) for 1 
hour at room temperature, followed by neutralization in 0.1M Borate Buffer (pH 8.5). The tissue 
sections were blocked with 10% normal goat serum (Vector Laboratories, Burlingame, CA, USA) 
and incubated overnight in primary antibodies targeting BrdU (1:100, Developmental Studies 
Hybridoma Bank, Iowa City, IA, USA). Secondary antibodies targeting IgG1 (AlexaFluor-488, 
Invitrogen-ThermoFisher Scientific, Carlsbad CA, USA) were used for fluorescent imaging of 
BrdU+ nuclei. Images were captured with a Nikon E800 microscope. BrdU+ cells were quantified 
using ImageJ software (National Institutes of Health, Bethesda, Maryland). BrdU+ labeled nuclei 
were quantified if they could be clearly associated with either the periphery or interior of a muscle 
fiber. All of the nuclei from six nonoverlapping fields were quantified with light microscopy at an 
objective magnification of 40X. There were two repeats for each biological section and the data 
averaged for each section. The BrdU labeling index was expressed as a percent of the total nuclei 
and determined by: (the number of BrdU-positive nuclei associated with muscle fibers)/(labeled 
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unlabeled nuclei associated with muscle fibers). Data are presented as mean ± standard 
deviation. 
2.3.5 Fiber-Type Immunohistochemistry.  
Muscle fiber types were identified using antibodies to myosin heavy chains (MHC) as 
previously reported by Bloemberg and Quadrilatero [35], with slight modifications as reported by 
our lab [24]. Briefly, isolated muscles were flash frozen in 2-methylbutane chilled by liquid nitrogen 
and mounted on corkboard with Tissue Tek O.C.T. compound (ThermoFisher Scientific, 
Pittsburgh PA, USA). Muscle tissue cross sections were obtained at -20°C with a Leica model 
CM3050S cryostat. Tissue sections were blocked with normal goat serum (Vector Labs, 
Burlingame, CA, USA) and stained with primary antibodies targeting MHC I (BA-F8S), MHC IIa 
(SC-71), and MHC IIb (BF-F3), at a 1:100 dilution overnight at 4°C in a humidified chamber. 
Primary antibodies were obtained from the Developmental Studies Hybridoma Bank, Iowa City, 
IA USA. After washing with PBS, the slides were incubated in secondary antibodies at a 1:500 
dilution for 2 hours at room temperature. Secondary antibodies targeting IgG2b (AlexaFluor-647), 
IgGM (AlexaFluor-546), and IgG1 (AlexaFluor-488), were obtained from Invitrogen-ThermoFisher 
Scientific, Carlsbad CA, USA, and were used for fluorescent imaging. Images were captured with 
a Nikon E800 microscope. Fiber cross sectional areas were determined by planimetry from a 
minimum of 500 fibers taken from 8-12 randomly selected fields from the tissue cross sections. 
All the fibers encompassed in a field were traced. Mean fiber area was calculated using ImageJ 
software (National Institutes of Health, Bethesda, Maryland). The cross-sectional images were 
captured with a Nikon E800 microscope. Whole muscle CSA was determined by tracing the entire 
circumference of the muscle section if the section could be captured as a single image, or 
otherwise as the summation of total muscle area traced from a composite picture. Type I fiber 
CSA was determined by individually tracing all fluorescently labeled fibers within a given section, 
with (n=3) muscle sections per group.  
41 
 
2.3.6 Satellite Cell Isolation.  
To evaluate the role of SIRT1 on the potential for repair during aging,  mononuclear muscle 
cells were isolated from the combined muscle mass of control non-CTX injured mouse TA and 
quadriceps muscles from both hindlimbs using the protocol of Pasut, and colleagues [36] with 
some modifications.  Briefly, muscle samples were cut into small sections and incubated in 1500 
U collagenase type II (Worthington Biochemical, USA) in DMEM + 10% horse serum, followed by 
incubation in 300 U collagenase type II with 6U dispase (Gibco, Invitrogen, Gaithersburg, MD, 
USA) in DMEM + 10% horse serum. After trituration, muscle supernatants were collected and 
filtered through 40 μm cell strainers (ThermoFisher Scientific, Pittsburgh PA, USA). Aliquots of 
isolated mononuclear cells were then washed in PBS-azide and blocked in 10% normal goat 
serum (Vector Labs, Burlingame, CA, USA). Satellite cells were separated from the muscle 
mononuclear cells by labeling the cells with fluorophore-conjugated primary antibodies as 
modified from methods described by Liu et al. [37]. Briefly, isolated mononuclear cells were 
labeled with fluorophore-conjugated primary antibodies for the following cell surface markers: 
CD31 (-APC), Sca-1 (-PacBlue), CD45 (-PE-Cy7), and VCAM-1 (-Biotin) (BioLegend, San Diego, 
CA, USA). A second incubation was used to bind Rhodamine-conjugated avidin (Vector Labs, 
Burlingame, CA, USA) to the biotin-conjugated antibody. After washing, the fluorophore-
conjugated cells were resuspended in fetal bovine serum (FBS) and VCAM+/CD31-/CD45-/Sca-1- 
satellite cells were isolated by a FACS Calibur flow cytometer equipped with a 15-MW 488nm 
argon laser and 633 nm red diode laser (Becton and Dickinson). All flow cytometric 
measurements were performed in conjunction with the West Virginia University Flow Cytometry 
Core Facility. 
2.3.7 Protein immunoprecipitation Assays.  
Immunoprecipitation of selected proteins from cell lysates was conducted as previously 
reported [38] Briefly, muscle cells were fractionated by the method described by the Rothaermel 
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et al. [39]. Protein isolates from skeletal muscles were incubated for 1h at 4°C with 25μL Pierce 
Protein A/G magnetic beads (ThermoFisher Scientific, Pittsburgh PA, USA) to reduce non-specific 
binding. Clean antigen solutions were then incubated for 2h at 4°C with an anti-PGC1α primary 
antibody (Santa Cruz Biotech. Sant Cruz, CA, USA). Pre-cleaned Protein A/G beads were next 
added to the antigen/antibody mixture and allowed to incubate overnight at 4°C. After the 
incubation, the protein A/G beads were collected with a magnetic apparatus and the supernatant 
was discarded. After washing, the magnetic beads were again collected, and the precipitated 
proteins were eluted with a 1x NuPAGE LDS sample buffer (ThermoFisher Scientific, Pittsburgh 
PA, USA) for 20min at room temperature. Protein concentrations of samples were determined by 
the Lowry method, and the purity of each fraction was confirmed as reported previously [40]. Forty 
micrograms of protein were loaded into each well of a 4–12% gradient polyacrylamide gel 
(Invitrogen, Carlsbad, CA) and separated by routine sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) for 1 h at 120 V. The proteins were transferred to a nitrocellulose 
membrane for 1.5 h at 25 V. Nonspecific protein binding was blocked by incubating the 
membranes in 5% nonfat milk in Tris-buffered saline containing 0.05% Tween 20 [24,41,42]. 
2.3.8 Mitochondrial Isolation.  
To evaluate the effect of SIRT1 on mitochondria, right and left non-CTX injured hindlimb 
plantar flexor muscles were collected from YWT and older SIRT1 variant-expression models, with 
both hindlimb flexor groups were pooled into a single sample. Collected tissues were washed in 
phosphate-buffered saline (pH 7.4). Subsarcolemmal mitochondria (SSM) and interfibrillar 
mitochondria (IFM) were isolated as previously described [43,44]. Mitochondrial pellets were 
resuspended in KME buffer (100mM KCl, 50mM MOPS, and 0.5mM EDTA; pH 7.4) for analysis 
of mitochondrial enzymatic activity [45,46]. 
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2.3.9 Mitochondrial Size, Internal Complexity, and Membrane Potential.  
The size, internal complexity/granulation, and membrane potential of isolated 
mitochondria were analyzed with a FACSCalibur flow cytometer equipped with a 15-MW 488nm 
argon laser and 633nm red diode laser (Becton and Dickinson, Franklin Lakes, NJ, USA), as 
previously described [43,45]. The ratiometric dye 5,5’,6,6’-tetrachloro-1,1’,3,3’-
tetraethylbenzimidazol carbocyanine iodide (JC-1; Molecular Probes, Carlsbad, CA) was used to 
selectively probe and gate for respiring mitochondria [47] using 488 nm excitation with 530 nm 
and 590 nm bandpass emission filters. A greater concentration of JC-1 aggregates form as a 
result of greater mitochondrial uptake, which increases the orange fluorescent emission signal, 
as opposed to the green fluorescent monomer of JC-1. The resultant ratio of orange fluorescence 
(polarized mitochondrial membrane) to green fluorescence (depolarized mitochondrial 
membrane) was used to characterize membrane potential for isolated mitochondrial 
subpopulations. 
Size and internal complexity/granularity were determined for mitochondrial populations 
with forward-scatter (FSC; absolute particle size) and side-scatter (SSC; refracted light 
proportional to mitochondrial granularity) detectors, respectively. All flow cytometric 
measurements were performed in conjunction with the West Virginia University Flow Cytometry 
Core Facility. 
2.3.10 Mitochondrial electron transport chain complex activities.  
The activities of mitochondrial complex I, III, and IV and ATP synthase were determined 
as previously described [43]. Complex I and ATP synthase activities were determined separately 
by measuring the oxidation of NADH at 340 nm, while complex III and complex IV activities were 
determined separately by measuring the reduction and oxidation of cytochrome c at 550nm, 
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respectively. Protein content was determined with the Bradford method and all complex activities 
were expressed in nanomoles of oxygen consumed per minute per milligram protein.  
2.3.11 Muscle force and fatigue.  
Young wild-type (YWT) and older SIRT1 variant-expression mouse models underwent measures 
to determine plantar flexor force and fatigability to assess the role of SIRT1 on muscle recovery 
post CTX injection. Functional measures were obtained via indirect electric stimulation of the 
plantar flexor muscles through the tibial nerve and measured with a custom-built dynamometer 
(Aurora Scientific, Aurora, Ontario, Canada) as previously described [24,38] with the mice 
anesthetized under 2-3% isoflurane.  
Electrically evoked contractions (200s pulse width) were measured with the mice on a 
heated plate to maintain body temperature under anesthesia. Hindlimb ankles were positioned at 
90° flexion. The functional assessment began with a three electrically evoked muscle twitches, 
followed by a 120s rest. A second stimulation of 75Hz, was then applied to induce tetanus followed 
by a 300s rest. This was repeated three times. Finally, a single series of 180 contractions were 
performed at 40Hz (330ms activation followed by 670 ms of rest) over a span of 180s. All 
stimulations were applied to the common peroneal nerve with subcutaneous platinum electrons 
with 200 μs pulse width, via commercially available stimulator and controlling software provided 
by Aurora Scientific (Aurora, Ontario, Canada). Mice were checked continually for vitality and 
responsiveness. After the functional evaluation, the right hindlimb gastrocnemius and soleus 
muscles were each injected with 100μL of 10μM CTX (Naja mossambica) to induce muscle 
damage [34] as described above. An equal volume of PBS was injected into the contralateral leg 
as a vector control. Muscle recovery/repair occurred for 21 days after CTX injection and then the 
plantar flexors were examined using the same physiological evaluation. Immediately following the 
functional measures, the mice were euthanized by myocardial extraction under heavy anesthesia 
and the hindlimb muscles were collected for analysis.  
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2.3.12 Proliferation Analysis.  
The proliferation potential of isolated populations of satellite cells was quantified from 
CTX-injected and control TA muscles using Click-iT EdU Alexa Fluor 488 (Invitrogen-
ThermoFisher Scientific, Carlsbad CA, USA). Briefly, satellite cells were isolated from TA muscles 
as described above. The isolated cells were then resuspended in growth medium Dulbecco’s 
modified Eagle’s medium (DMEM; high glucose, L-glutamine) with 20% fetal bovine serum (FBS), 
10% horse serum (HS), and 1% antibiotic/antimycotic (Gibco, Invitrogen, Gaithersburg, MD, USA) 
and plated overnight on glass coverslips coated in 0.2% gelatin. Plated satellite cells were then 
incubated for 1 hour in 10μM EdU in DMEM. After incubation, the cells were fixed in 1mL of 3.7% 
formaldehyde in PBS for 15 minutes at room temperature, then washed twice with 1mL of 3% 
bovine serum albumin (BSA) in PBS. The cells were then permeabilized in 1mL of 0.5% Triton X-
100 in PBS for 20min. After a second wash in PBS +3% BSA, cells were treated with 500μL of 
reaction buffer, consisting of copper sulfate, the Alexa Fluor-conjugated azide, and sodium 
ascorbate, then allowed to incubate for 30 min at room temperature, protected from light. The 
cells then underwent a final wash and were transferred to microscope slides for analysis with a 
Nikon E800 microscope. Coefficients of proliferation were calculated as the number of illuminated 
cells counted on 9 separate fields divided by the number of cells plated. Experiments were run in 
triplicate and are presented as the mean ± standard deviation.  
2.3.13 Western Blot Analysis.  
Skeletal muscle lysates were analyzed with Western immunoblots as previously described 
[24,38,41,42], with slight modifications. SDS-PAGE was run on 4-12% gradient NuPAGE Bis-Tris 
gels (ThermoFisher Scientific, Pittsburgh PA, USA) at 120V for 2h in NuPAGE MES SDS buffer 
(ThermoFisher Scientific, Pittsburgh PA, USA). Proteins were transferred to a nitrocellulose 
membrane for 1h at 15V with a Trans-Blot SD semi-dry transfer cell (Bio-Rad). All proteins were 
probed at the same time from the same samples, requiring only GADPH loading control. 
46 
 
Membranes were then carefully cut to separate the proteins based on protein molecular weight 
(MW) to allow for the simultaneous probing of multiple different proteins for each treatment group. 
The MW for the proteins were: FoxO3a (80kDA), p53 (53kDA) and GAPDH (35.8kDA). After 
blocking with TBST + 5% nonfat dry milk, membranes were incubated overnight at 4°C in 1:1000 
dilutions of primary antibodies for Sirt1 (Millipore), PGC1α (Santa Cruz), GAPDH (Cell Signaling, 
Danvers, MA, USA), p53 (Cell Signaling, Danvers, MA, USA), Acetyl-Lysine (Cell Signaling, 
Danvers, MA, USA), and FOXO3a (Cell Signaling, Danvers, MA, USA). Membranes were then 
incubated in HRP-linked anti-mouse and anti-rabbit secondary antibodies at 1:5000 dilutions (Cell 
Signaling, Danvers, MA, USA). HRP signals were developed with an enhanced chemiluminescent 
substrate (ThermoFisher Scientific, Pittsburgh PA, USA) with a G:Box Bioimaging System 
(Syngene, Fredrick, MD, USA). Band intensity was normalized to GAPDH.  
2.3.14 Verification of antibody specificity.  
The antibodies which were used in our experiments were validated prior to utilization. We 
obtained antibodies that were supplied from vendors which were able to provide validation, 
maintenance testing and production validation to ensure that lots of the antibodies remained 
constant over the study duration. In addition, validation of the antibodies included testing on 
appropriate positive protein controls or mouse models (deficient in gene/protein) by immunoblot 
and immunostaining. Western blots were conducted to validate band sizes, and 
immunohistochemistry on each antibody to check for non-specific staining in tissue sections. 
Several different antibodies to the same protein were used to confirm staining patterns and/or 
location of the protein band on a western blot. Negative controls were conducted without the 
primary antibody or without the secondary antibody to confirm that there was no inappropriate 
cross-labeling by the antibodies.  
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2.3.15 Statistical Analysis.  
Quantitative analysis was performed on experiments done at least in triplicate. Statistically 
significant differences between groups were determined using GraphPad Prism 6 software (La 
Jolla, CA, USA) performing a Two-way ANOVA (age group x condition) with corrections made for 
multiple comparisons against a baseline control group by the Dunnett’s test. Fatigue analysis was 
performed using Two-way Repeated ANOVA analysis with corrections for multiple comparisons 
against the baseline control. Statistical differences between right and left hindlimb pre-treatment 
groups for each genotype were compared using paired t-tests for muscle force, indicating the 
difference between hindlimbs was not significant from zero. Multiple unpaired t-tests for contractile 
force as a function of the number of muscle contractions was also performed between the left and 
right hindlimb pre-treatment groups for each genotype, also indicating no significant difference 
between hindlimb function within the individual models. As such, data for the left hindlimb pre-
treatment groups were expressed as baseline data for each model. Unpaired t-tests were also 
used, when appropriate, to determine statistical significance between two groups, such as 
treatment and control groups within each genotype, with significant differences noted when 
present. Effect sizes were reported using the Cohen’s d statistic and were calculated as the 
difference in means over the pooled standard deviation. The results were expressed as mean ± 
standard deviation (SD), (P < 0.05). 
2.4 Results 
2.4.1 Animal Model Characteristics.  
Mouse models were categorized into five groups, based on age and SIRT1 expression. 
Young wild-type (YWT) mice were 20-30 weeks old, while older mice were 80-120 weeks of age. 
The older mice included: wild-type mice (WT-80), SIRT1 overexpressor mice (OE-80), SIRT1 
adult skeletal-muscle knockout mice (MKO-80), and SIRT1 satellite cell knockout mice (SKO-80). 
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Each group included both male and female mice. Although the older mouse groups showed no 
significant differences in body weight between males and females, YWT females were 
significantly smaller than corresponding YWT males (P ≤ 0.05) (Table 1).  
2.4.2 SIRT 1 protein abundance in the mouse models.  
To characterize differences in SIRT1 protein abundance between animal groups, the 
hindlimb muscles were collected from young wild-type (YWT, n=3) and older (80+ weeks) wild-
type (WT-80, n=3), SIRT1 overexpressor (OE-80, n=3), SIRT1 skeletal muscle knockout (MKO-
80, n=3), and SIRT1 satellite cell knockout (SKO-80, n=3) mice, 21 days after phosphate buffered 
saline (PBS) or cardiotoxin (CTX) injection. The mice were examined prior to and 2 hours after 
exercise (-ex) because exercise is a known inducer of SIRT1 [48]. As expected, SIRT1 was 
greater in the OE muscles and lowest in the muscles from SKO and MKO mice (Fig. 1B). These 
data indicate that SIRT1 protein levels were as anticipated based on the crosses of the respective 
animal models. SIRT1 was not absent in SKO-80 mice muscles, although the SIRT1 protein 
abundance was significantly lower in PBS-injected, but not CTX-injected hindlimb muscles from 
SKO-80 relative to YWT mice. Interestingly, ANOVA analyses showed significant differences 
between the OE-80 PBS and SKO-80 PBS groups as compared to wild-type controls, but not the 
MKO-80 PBS groups. However, the OE-80, SKO-80, and MKO-80 muscle SIRT1 abundances 
were significantly different from the wild-type controls when compared with individual t-tests (P < 
0.05, data not shown). Only the muscles from SKO-80 mice showed a significant increase in 
SIRT1 abundance in CTX-injected muscles relative to their own PBS group (P < 0.05). 
We next measured FoxO3a and p53 protein abundance because they are downstream 
targets of SIRT1 (Fig. 1C). Protein abundance was not markedly different for FoxO3a among the 
groups. Abundance of p53 followed a similar distribution to the SIRT1 protein expression, 
although a significant difference in p53 protein abundance was not detected between the OE-80 
groups and the YWT PBS control (Fig. 1D). Interestingly, while a significant increase in p53 
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protein abundance was not detected between injury-recovered muscles and muscles treated with 
the saline control for either the OE-80 or MKO-80 groups, the relative abundance of p53 for those 
groups was significantly greater than the p53 abundance detected in muscles from the YWT CTX-
injected mice (comparison denoted by #). Even though the muscle protein abundance of p53 in 
the YWT CTX mice differed significantly from the protein abundance levels in muscles from the 
OE-80 CTX and the MKO-80 CTX groups, p53 protein abundance in muscles from YWT CTX-
injected mice did not differ significantly from the levels found in muscles from the WT-80 CTX and 
the SKO-80 CTX groups (Fig. 2C-H).  
We also evaluated the acetylation status of PGC1α, another downstream target of SIRT1 
to assess SIRT1 activity (Fig. 1E). Although we expected to see decreased acetylation of PGC1α 
in muscles from the SIRT1 overexpressor mouse model and increased acetylation in the muscles 
from SIRT1 knockout mice, qualitative analysis of immunoblots showed no apparent change in 
acetylation state, regardless of apparent PGC1α expression in the various mouse genotypes (Fig. 
1F).  
2.4.3 Skeletal Muscle Function.  
2.4.3.1 Muscle Force.  
We tested whether SIRT1 protein abundance had a role in regulating skeletal muscle 
function in muscles of older mice after acute injury induced by cardiotoxin (CTX). Before 
treatment, average, evoked maximal plantar flexion contractile force at 75 Hz stimulation was 
significantly lower in the older SKO-80 mice as compared to YWT PRE, indicating a lower basal 
contraction force in older mice deficit of SIRT1 in satellite cell (Fig. 2A). Next, contractile force 
was assessed in each group following a 21-day recovery from acute injury by CTX or treatment 
with PBS to determine if SIRT1 abundance in skeletal muscle had an effect on the recovery of 
contractile function. Mean maximal contractile force in YWT mice generated at a stimulation 
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frequency of 75Hz had recovered to control levels by 21 days after CTX-treatment. The maximal 
contractile force was significantly lower in the PBS-injected, vector control hindlimb for WT-80 
compared to the WT-80 PRE baseline, suggesting that the older muscles in the WT-80 animals 
may have been susceptible to injection- injury (Fig. 2A). As expected, aging per se resulted in a 
lower plantar flexion maximal force production in wild-type mice, as seen by the lower force 
production in the muscles of the WT-80 PBS group relative to the WT-80 PRE group.  
We next compared the percent recovery of contractile force in hindlimb muscles 21 days 
post-recovery from CTX injection (Fig. 2B). The maximal post PBS- or CTX-injection plantar 
flexion force was normalized to the respective pre-treatment force output for each animal. The 
aged mice were expected to show decreased force recovery in PBS control hindlimbs relative to 
the young wild-type mice. However, despite the WT-80 having a force recovery under 1-fold, no 
older group showed significantly altered, basal force recovery in control PBS injected hindlimbs 
relative to the YWT PBS group. This suggests that aging did not impair recovery after injury. 
Contrary to our original expectations, only the youngest group of mice (YWT) showed decreased 
recovery in maximal hindlimb force from muscles that had been acutely injured by CTX as 
compared to PBS treated muscles. Although the overall plantar flexion force output for SKO-80 
hindlimb muscles was significantly lower than YWT mice, the SKO-80 mice appeared to recover 
to pre-treatment levels after 21 days of recovery. The relative force produced 21 days after CTX-
induced injury was not diminished in the older SKO-80 animals as compared to young animals 
although the absolute levels of force was also depressed in the SKO-80 animals as compared to 
other groups. 
2.4.3.2 Muscle fatigue.  
Muscle fatigability was examined in hindlimb plantar flexor muscles from young and older 
mice by inducing a series of 180 electrically evoke contractions at 40 Hz over a period of 3 
minutes. While the mean force output over time shows the amount of fatigue occurring in a 
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contracting muscle group, it does not necessarily mimic resistance to fatigue for those muscles. 
Therefore, we examined fatigue resistance by looking at the depletion of muscle contractile force 
as a function of consecutive electrically evoked contractions by normalizing the force of each 40 
Hz contraction to the force of the initial 40Hz contraction (Fig. 2C-H). The baseline fatigability of 
the young, pre-treatment wild-type mice (YWT PRE) mice did not differ significantly from the 
fatigability of the WT-80 PRE, OE-80 PRE, MKO-80 PRE, or SKO-80 PRE-groups (Fig. 2D, H). 
Neither acute muscle injury from CTX, nor injection with the PBS vector control, had significant 
effects on muscle fatigability in YWT, WT-80, or SKO-80 mice post-recovery (Fig. 2D, E, H). 
Surprisingly, muscles that underwent repair after CTX injury had greater fatigue resistance in both 
the aged SIRT1 overexpression and skeletal muscle knockout models of SIRT1 (Fig. 2F, G). The 
OE-80 CTX group showed the greatest magnitude and most consistent attenuation of fatigue 
following recovery from acute muscle injury, and the OE-80 CTX was also the only group to show 
signs of post-activation potentiation, so that muscle contractile force increases with time rather 
than diminishing. Although the effect was smaller for the MKO-80 CTX group compared to the 
OE-80 CTX mice, protection from fatigue was present only in muscles that had recovered from 
acute CTX injury (Fig. 2E-G), which would have required activation of satellite cells to induce 
repair. Interestingly, when compared to the fatigability of YWT CTX mice, the OE-80 CTX and 
MKO-80 CTX groups still showed significant protective fatigue resistance, albeit to a lesser 
degree, and were the only groups to do so. Furthermore, the fatigue resistance seen in the OE-
80 CTX and MKO-80 CTX models coincides with the increased abundance of p53 after repair 
from CTX as seen in Figure 1C.  
2.4.4 Fiber cross sectional area.  
Given the greater susceptibility of type II fibers to aging-induced atrophy [49] and the 
general resistance of type I fibers to sarcopenic changes [50], we decided to investigate the effect 
of SIRT1 expression on these two primary muscle fiber types in the gastrocnemius muscle of 
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older mice. Although the exact fiber type distribution of the mouse gastrocnemius can vary 
between strains, the gastrocnemius muscle typically contains a mixture of type I and type II 
muscle fibers although it is predominantly composed of type II fibers [51]. To determine the effects 
of SIRT1 expression on gastrocnemius muscle structure after acute injury, we used 
immunofluorescence techniques to determine the cross-sectional area (CSA) of whole muscles, 
and type I and type II fibers from PBS- and CTX-injected gastrocnemius muscles of the YWT and 
older groups (Fig. 3F-H). As expected, the CSA for the gastrocnemius muscle was lower in older 
mice 21 days after PBS- or CTX-injection CSA relative to muscles in YWT mice 21 days after 
PBS (Fig. 3F). However, we did not find a significant difference between any older group and the 
YWT control. Given that the Cohen’s d test shows effect sizes greater than 2 standard deviations 
for two groups (WT-80 PBS and WT-80 CTX), it is likely that the absence of significance may 
have been due to a low sample size.  
Similarly, the CSA in the soleus muscle (Fig. 3G), had a significant F statistical main effect 
from One-Way ANOVA with corrections for multiple comparisons, however, no groups had 
significant differences were found between the YWT PBS control group and other groups.  Groups 
of mice showing a large effect size (>1 standard deviation) were YWT CTX, WT-80 PBS, OE-80 
CTX, and SKO-80 CTX groups. Next, we calculated mean type I fiber CSA from each 
gastrocnemius section (Fig. 3A-E), from which we calculated the percent type I CSA standardized 
to the total CSA of the gastrocnemius muscle (Fig. 3H). Despite the apparent difference of the 
percent of type I fibers, this did not reach a statistically significant difference when represented 
as a percentage of the entire gastrocnemius muscle CSA or the specific comparisons of the 
treatment groups to the YWT PBS control.  
2.4.5 Regenerative Capacity 
Loss of function in aging skeletal muscle is characterized by reduced capacity for muscle 
satellite cells to regenerate damaged tissue [52]. Previously, our lab has used 5-bromo-2’-
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deoxyuridine (BrdU) administered in water supplied ad libitum to gauge satellite cell proliferation 
to an experimental intervention [24]. Therefore, to examine satellite cell division in response to 
skeletal muscle regeneration, we injected the tibialis anterior (TA) muscles of older WT, OE, MKO, 
and SKO mice with CTX or PBS as a control and supplied the recovering mice with 0.8mg/mL 
BrdU for 21 days post-injury. After recovery, the mice were sacrificed and BrdU expression was 
identified in the TA or gastrocnemius muscles by immunohistochemically. The number of BrdU+ 
nuclei in CTX-recovery hindlimb muscles were then counted (Fig. 4A-D) and normalized to the 
CSA of their respective muscles. In contrast to the plantar flexor muscle group, the TAs showed 
no significant difference between PBS and CTX-recovery groups for mean muscle CSA or effect 
size (Fig. 4E). No significant difference was seen between the MKO-80 and WT-80 groups, while 
a significantly lower number of BrdU+ nuclei/μm2 was found for the OE-80 and SKO-80 CTX-
recovery groups (Fig. 4F). Nevertheless, all animal groups showed effect sizes larger than 1 
standard deviation (P ≤ 0.05).  
Next, to determine the regenerative capacity of satellite cells from the older SIRT1 
expression variable mouse models, we isolated satellite cells by FACS and used them in 
proliferation analysis. Isolated satellite cells were diluted so that 10,000 cells could be plated in 
triplicate onto a gelatin-coated coverslip in a 24 well plate. Cells were allowed to recover overnight 
before treatment with 5-ethynyl-2’-deoxyuridine (EdU) prior to fixation and permeabilization. 
Similar to BrdU, EdU is incorporated into DNA from proliferating cells. Thereafter, images from 9 
fields from each coverslip were captured and the total number of EdU+ cells were counted (Fig. 
5A-D).  The proliferation factor was calculated and expressed as the number of EdU+ cells in 9 
image fields over the number of cells initially plated. Satellite cells that were isolated from muscles 
of MKO-80 mice showed a significant increase in proliferation relative to WT-80 mice, with an 
effect size greater than 3 standard deviations (Fig. 5E).  
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2.4.6 Mitochondrial Structure and Function.  
There is likely a link between mitochondrial dysfunction and aging [53] including 
sarcopenia [4]. As SIRT1 is a known regulator of PGC1α which in turn regulates mitochondria 
biogenesis, we next decided to investigate the effects that SIRT1 expression levels had on 
mitochondrial activity in the skeletal muscle of older mice. To determine changes in mitochondrial 
size and complexity/granularity, freshly isolated interfibrillar mitochondria (IFM) and 
subsarcolemmal mitochondria (SSM) subpopulations were analyzed in control mice by forward-
scattering (FSC) and side-scattering (SSC) light, respectively [44,54]. Mitochondria were isolated 
from the same mice that were used for satellite cell isolation experiments and therefore it was not 
possible to evaluate mitochondria after CTX experiments in these mice. Older mice had greater 
mitochondrial size for both SSM and IFM relative to YWT control mice for both SIRT-1 
overexpressor and knockout groups (Fig. 6A, D). No significant difference was found for the 
internal complexities of IFM or SSM; however, a significant F ratio was found for the SSM internal 
complexity, despite having no significant differences among the groups relative to the YWT control 
(Fig. 6B, E).  
Changes in mitochondrial membrane potential (ΔΨm) typically occur in tangent with 
diseases like diabetes [45,54] and also in aging [55]. Isolated mitochondria were incubated with 
5,5’,6,6’-etrachloro-1,1’,3,3’-tetraethylbenzimidazol carbocyanine iodide (JC-1). A shift from JC-1 
green to red fluorescence indicated an increase in the ΔΨm. Previous studies have shown 
mitochondria from diabetic animals or humans had a greater orange/green ratio as compared to 
control mitochondria [45,54]. A significantly lower ΔΨm was found in SSM populations for OE-80 
mice relative to YWT control mice as reflected by a lower orange/green fluorescent ratio (Fig. 
6C). A similar decrease in ΔΨm was seen for the IFM mitochondria in OE-80 mice, although 
statistical significance was not achieved (Fig. 6F). While significant differences for ΔΨm were not 
found between groups, a One-way ANOVA with corrections for multiple variances with the 
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Dunnett’s test (p = 0.05), the global analyses revealed a statistical difference between the group 
means. Given the large effect sizes for some of the groups (>1 SD), it is possible that the 
marginally non-significant pairwise contrasts in (Fig. 6F) may have produced a significant 
difference if there the experimental sample size had been larger.  
2.4.7 Mitochondrial Complex Activity and Muscle Repair.  
To further examine the effects of variant SIRT1 expression coupled with aging on 
mitochondria, we next assessed the relative activity of the mitochondrial electron transport chain 
complexes in control muscles. These same mice were used for satellite cell isolation experiments 
and therefore it was not possible to evaluate mitochondria following CTX injury in these mice. 
Significant differences were found for activities of the SSM complexes; specifically, a greater 
complex III activity for WT-80 mice (Fig. 6H), and a reduced ATP-synthase activity for OE-80 
mice (Fig. 6J). No significant change was seen for SSM complex I activity (Fig. 6G) or SSM 
complex IV activity (Fig. 6I), although the One-Way ANOVA global test did suggest there was a 
significance in differences between the means.  No significant group differences were found for 
IFM complex I activity (Fig. 6K), complex III activity (Fig. 6L) or complex IV activity (Fig. 6M), 
however, the global analysis did show that a significant difference existed for the IFM ATP-
synthase activity (Fig. 6N).  
2.5 Discussion 
In skeletal muscle, SIRT1 has been established as a regulator of PGC1α and consequently, 
mitochondria [21,56], which are important for generating ATP during muscle repair. SIRT1 is 
generally high in type I fibers and promoted by endurance exercise [48], and because type I 
oxidative fibers are generally though to resist aging-related atrophy, SIRT1 has become a target 
of interest in studies of sarcopenia with a potential role in preventing muscle wasting. Support for 
this idea came from studies that show overexpression of SIRT1 prevented type I fiber atrophy 
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under conditions of long-term caloric deficit [15]. Furthermore, SIRT1 overexpression also 
improved the pathophysiology of muscle wasting including Duchenne muscular dystrophy [50]. 
The data in the present study show that SIRT1 is important for proper muscle function in older 
mice, with loss-of-function most impactful to muscle satellite cells. This suggests that SIRT1 may 
have a role in satellite cell regulated muscle repair. Unexpectedly, both our SIRT1 overexpressing 
model (OE-80) and skeletal muscle-specific SIRT1 knockout model (MKO-80), demonstrated 
increased resistance to muscle fatigue after recovering from acute CTX-induced muscle damage. 
Although knocking out SIRT1 in satellite cells impairs muscle contraction in aged mice, ablation 
of SIRT1 from skeletal muscle promotes satellite cell proliferation and therefore the muscle’s 
regenerative capacity, suggesting that the most beneficial or detrimental effects of SIRT1 may be 
determined by its site of localization within muscle cells.  
2.5.1 Muscle and satellite cell loss of SIRT1.  
Interestingly, the MKO and SKO models showed differential effects for SIRT1 knockout. 
The MKO mice had a greater resistance to fatigue after repair following CTX injury but a similar 
level of regenerative capacity as compared to the older models. In contrast to the SKO model, 
the cre protein in the MKO model is induced by the MCK promoter, so SIRT1 it is only expressed 
in mature skeletal muscle. In contrast, the SKO model’s cre protein is promoted by PAX7 so that 
SIRT1 is inactive in only satellite cells, but not in skeletal muscle when PAX7 is downregulated.  
2.5.2 Satellite cell but not muscle loss of SIRT1 reduces maximal force production.  
Muscles from older MKO mice did not have a loss of muscle force production when 
compared to age-matched or 20-week-old, wild-type control mice. This suggests that loss or gain 
of SIRT1 does not affect the muscle’s ability to generate maximal muscle force (presumably by 
not affecting the number or general function of the myosin cross bridges). In contrast, SKO mice 
that have a satellite cell specific loss of SIRT1 had lower overall plantarflexion force than young 
57 
 
or older wildtype or SIRT1 overexpressor mice, although gastrocnemius and soleus muscles were 
not markedly smaller in this group. This suggests that loss of SIRT1 in satellite cells did not 
change overall cross bridge number in the muscle’s CSA, but interestingly it did affect muscle 
function. While it is possible that SIRT1 could affect force per cross bridge, we think a more likely 
possibility is that the lower force output in muscles from SKO mice may indicate a neural problem 
which resulted in an incomplete activation of muscle in the old mice. This could potentially occur 
at the level of the neuromuscular junction perhaps as an accelerated aging loss of dystrophin [57]. 
However, this study was not designed to evaluate the role of SIRT1 in neural regulation of force. 
2.5.3 SIRT1 expression may improve but is not necessary for recovery of muscle function 
after injury.  
Muscle repair is dependent upon satellite cell activation and satellite cell function thought 
to be depressed with aging [23,52].  In elderly humans, SIRT1 activation by resveratrol was shown 
to be associated with increased satellite cell activation in response to loading exercise [27].  
Although the MKO-80 and OE-80 aged models in our study vary with respect to their levels of 
SIRT1 expression in skeletal muscle, both groups showed some improvement in fatigue 
resistance in response to repeated contractions of muscles in hindlimbs previously injured by CTX 
as compared to uninjured control muscles. This fatigue resistance was not reproduced in CTX-
injured hindlimbs for the YWT, WT-80, or SKO-80 models after a 21-day recovery period that was 
observed in the other groups. Furthermore, none of the 5 animal groups experienced a loss of 
function during the fatigue testing in hindlimbs injured by CTX or injected with the PBS control, 
indicating that functional recovery of skeletal muscle is not influenced by loss or gain of SIRT1 
abundance in skeletal muscle. The gain of function after injury in both SIRT1 overexpressor and 
SIRT1 knockout models suggests a common repair-induced modification in muscle function may 
exist as long as some SIRT1 is present in satellite cells (even if it does not exist in the muscle 
cells per se).  
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2.5.4 SIRT1 loss in muscle increases acute, but not long-term proliferation of satellite cell. 
 Ryall and colleagues reported that knocking SIRT1 out of satellite cells caused premature 
differentiation of satellite cells [29], and therefore we expected SIRT1 loss or overexpression 
would induce different satellite cell proliferation responses after CTX injury.  
In vitro analysis of cell proliferation within 24 hours of culturing isolated satellite cells 
showed that a muscle knockout of SIRT1 had the greatest potential for satellite cell proliferation 
among the experimental groups. Of the five experimental groups, only the MKO model lacked 
expression of SIRT1 in skeletal muscle (despite PAX7 not being expressed in skeletal muscle, 
Western blots showed reduced or ablated bands for SKO mice, which should only lack SIRT1 in 
satellite cells). However, because the SKO muscles showed a comparatively blunted level of 
proliferation compared to the MKO model, muscle loss of SIRT1 while maintaining satellite cell 
SIRT1 appeared to increase satellite cell proliferation. However, this potential was not realized in 
vivo in response to repair following CTX injury. 
In vivo proliferation was assessed 21 days after acute CTX injury in muscles of older mice 
and was reflected by the frequency of BrdU+ nuclei present in muscle sections post-repair. As 21 
days represents a point where recovery from acute injury should be complete, this experiment 
reflected long-term satellite cell proliferation following an acute injury and not the rate of cell 
proliferation. After 21 days, the MKO model no longer had the greatest proliferation capacity, but 
instead was the only SIRT1-expressor variant that did not differ significantly in the number of 
BrdU+ nuclei quantified in the older, WT-80 group. Both OE-80 and SKO-80 showed significantly 
fewer BrdU+ cells relative to the WT-80 and MKO-80 models. This indicates that factors outside 
of the satellite cells (potentially cross-talk between muscle and satellite cells) in vivo limited 
satellite cell proliferation in muscles of old animals, and one of those could be muscle SIRT1. 
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2.5.5 Mitochondrial function and SIRT1 in muscle. 
As SIRT1 has a role in regulating oxidative metabolism and connecting global metabolism 
to longevity and regeneration, we also examined mitochondrial subpopulations to identify potential 
differences in these subpopulations resulting from variant SIRT1 expression. Mitochondrial 
dysfunction may be a fundamental component that regulates aging responses along several 
pathways [27,58]. Previous work has suggested that interfibrillar mitochondria (IFM) and 
subsarcolemmal mitochondria (SSM) subpopulations are affected differently in cardiac muscle by 
diabetes [54]. Furthermore, SIRT1 is a regulator of PGC1- which moderates mitochondrial 
proliferation [59].  
As a reduced mitochondrial membrane potential has been characterized as an effect of 
aging and correlates with increased ROS production [55,60] we had expected that mitochondrial 
membrane potential (ΔΨm) would be improved when SIRT1 was overexpressed in muscles of 
older mice, but this was not the case. Interestingly, we saw that muscles from older mice 
overexpressing SIRT1 had a significantly lower ΔΨm and ATP-synthase activity in the SSM 
subpopulation. While, we found a significant F ratio for IFM ΔΨm by One-way ANOVA, there was 
no significance difference in the mitochondrial membrane potential as an indicator of 
mitochondrial function between animal groups (denoted in our figures by F*), for IFM-ΔΨm and 
IFM ATP-synthase activity. The IFM results may have been a function of significant differences in 
activity that were masked by the low sample sizes of the experiments. While it is possible that the 
decrease in ΔΨm in muscle mitochondria from SIRT1 overexpressor mice, may extend to the IFM 
subpopulation as well, we cannot verify this in the current study.  
Despite loss of SIRT1 function, there was no significant differences in muscle 
mitochondrial characteristics among MKO-80, SKO-80 and YWT mice aside from significantly 
increased size in the older mice (perhaps as a function of decreased mitochondrial fission or 
increased fusion). Because analysis of these mitochondria was performed on isolated skeletal 
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muscle and not isolated satellite cells, some differences in mitochondrial characteristics may be 
present during the repair process in satellite cells that could contribute to a reduced maximal 
contraction force in muscles of SKO-80 mice, or the increase in proliferation of satellite cells seen 
in MKO-80 mice. However, the similarities between the experimental models for the majority of 
the mitochondrial factors closely reflects the physiological data that showed little change between 
muscle fatigability between pre-treatment and saline-injected control groups. Although the 
reduced ΔΨm and ATP synthase activity in SSM from OE-80 mice, coupled with the significantly 
reduced number of proliferating BrdU+ cells detected after injury, support the idea that 
mitochondria dysfunction may impair the recovery of muscle injury in aging [61]. The force and 
fatigue data collected before and after injury suggest that alterations in mitochondria 
characteristics did not impair muscle function after repair from CTX-induced injury. 
One explanation for the increased satellite cell proliferation seen in MKO-80 mice after 
injury and the blunted satellite cell response seen in the OE-80 model might be related to the 
mitochondrial related reactive oxygen species (ROS) concentration in the relative cellular 
environments. For example, attenuation of muscle regeneration in satellite cells from old mice 
was shown to decrease when aged satellite cells were paired to young circulatory environments 
[23], indicating that repair can be influenced by the local cellular environment. Several studies 
have suggested that excess ROS generated from mitochondrial respiration can damage cellular 
structures and may contribute to cellular aging [62]. It is possible, although speculative, that 
skeletal muscle containing high levels of SIRT1 may release more mitochondrial-associated ROS 
than SIRT1 knockout models during injury and repair, and thereby impair the proliferation capacity 
in satellite cells during muscle repair. Although our study was not designed to measure ROS 
levels, we did see a reduction in SSM- ΔΨm and in ATP synthase activity for the OE-80 model. 
Reduced NAD+ and SIRT1 activity has been observed in aged tissues, concurrent with reduced 
mitochondrial respiratory chain activity and decreased expression of proteins that protect against 
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oxidative damage [63]. Conversely, treatment with nicotinamide (NAM), the precursor to the 
SIRT1 cofactor nicotinamide adenine dinucleotide (NAD+), has been shown to increase 
mitochondrial membrane potential and decrease ROS concentration through pathways utilizing 
[64], and pathways independent of SIRT1 [65]. It is possible that the OE-80 model, which has 
increased expression of SIRT1 and a decreased SSM- ΔΨm, is depleting NAD+ more than wild-
type or knockout models. If this was the case, NAM abundance would be decreased and ROS 
abundance would be increased, which in turn would be expected to reduce satellite cell 
proliferation as a result of greater oxidative damage. 
As resveratrol-mediated SIRT1 activation was shown to be protective against ROS-
induced mitochondrial-mediated apoptotic signaling in muscle [41], and SIRT1 increases 
antioxidant production in muscle [27,32] we had expected that mitochondrial function would be 
improved in muscles that overexpressed SIRT1after repair following CTX injury mice. However, 
muscles from OE-80 animals had the lowest SSM-ΔΨm and SSM ATP-synthase activity. As SSM 
lie close to satellite cells, we would have expected this mitochondrial subpopulation to have the 
greatest impact on proliferating satellite cells if mitochondrial were important for this process. 
Nevertheless, the abundance of BrdU positive satellite cell nuclei were not different in muscles 
among OE-80, MKO-80 or SKO animals after repair from CTX-injury. Thus, the potential for SIRT1 
abundance to alter mitochondria did not appear to affect the potential for satellite cell-proliferation 
during repair after CTX injury. 
2.5.6 p53 protein abundance is increased in SIRT1 variant models that gained improved 
muscle function after recovery from CTX-induced injury.  
Tumor suppressor p53 is a well-characterized downstream target of SIRT1. While SIRT1 
deacetylation usually inhibits p53 activity, p53 can be upregulated through several pathways, 
especially in response to cellular stress or damage 66. Indeed, p53 was only found to be 
significantly increased in the CTX-injured muscle of the OE-80 and MKO-80 models, but only 
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when compared to basal levels of p53 in control muscles that have also recovered from CTX 
injury. Because one of the main functions of p53 is to repair DNA in response to injury, the 
presence of p53 in the CTX-injured muscles provides a plausible explanation as to why our OE-
80 and MKO-80 mouse models that have opposite protein abundances of SIRT1 could 
paradoxically both benefit from CTX-induced injury. Furthermore, p53 has recently begun to 
emerge as an important factor in exercise metabolism, as genetic knockouts of p53 reduce IFM 
and SSM mitochondrial yield, inhibit mitochondrial respiration, and reduce exercise capacity 
during fatiguing exercises in rodent models [67]. Interestingly, although the expression of p53 
coincides with improved fatigue resistance in the SIRT1 muscle knockout, the improvement in 
muscle function after CTX-recovery is markedly greater in the OE-80 model, indicating high 
synergy between the abundances of the SIRT1 and the p53 proteins during muscle recovery.  
2.5.7 Expression of p53 may underlie the attenuation of MKO-induced satellite cell 
proliferation.  
Previous work has established that SIRT1 expression in satellite cells helps to maintain 
the quiescence of satellite cells, and that eliminating SIRT1 in satellite cells causes premature 
proliferation [29]. Normal downregulation of SIRT1 in satellite cells precedes a metabolic shift 
from fatty acid metabolism to glycolysis, which is a necessary step for the transition between 
quiescence and proliferation. Because the metabolic profile of stem cells also acts to regulate 
proliferation and differentiation [68], it is possible that the increased satellite cell proliferation seen 
in the MKO mouse model is due to the absence of SIRT1 in muscle that disrupts the necessary 
metabolic change required to end satellite cell proliferation. This possibility is strengthened by 
evidence showing that there is an increased abundance of p53 in the CTX-injected hindlimb 
muscles of the MKO mouse model and that there is an attenuation of satellite proliferation that 
was identified by BrdU+ 21 days post CTX injury. This is because overload-induced muscle 
growth increases nuclear p53 [69] and ablating p53 activity reduces myoblast differentiation [70]. 
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A likely scenario is that in the absence of SIRT1 in MKO muscle causes satellite cells to undergo 
increased proliferation (a reduced proliferation “off-signal”), while the overexpression of SIRT1 
would inhibit proliferation, which corresponds to a lower number of BrdU+ cells in the OE-80 
model when compared to WT-80. Ironically, CTX-induced muscle damage that should promote 
satellite cell proliferation to stimulate repair also increased p53 expression, which would be 
expected to inhibit proliferation and promote differentiation in satellite cells of the repairing 
muscles in MKO-80 mice and potentially lead to muscle growth/repair. This is consistent with the 
observation that cell proliferation was attenuated in isolated satellite cells from MKO-80 mice in 
vitro after 24 hours by EdU analysis.  
2.5.8 The synergistic effects of SIRT1 and p53 that improve fatigue resistance after injury 
may also protect type I fibers from sarcopenic wasting.  
Although the expression of p53 in the CTX-recovery hindlimbs of the MKO-80 mice 
provide a possible explanation as to why the MKO-80 mice have attenuated satellite cell 
proliferation after CTX injury and why injury may induce a protective effect against fatigue, the 
inhibitory effect that SIRT1 exerts on p53 suggests that co-expression in muscle fibers should 
ablate the protective effects of p53 on fatigability. To the contrary, our data show that the OE-80 
mice gain a strong protective effect against fatigue when p53 is upregulated in hindlimbs following 
CTX injury and even show signs of improving muscle function following injury through post-
activation potentiation [71,72]. One possible explanation is that the inhibition of p53 by SIRT1 only 
inhibits p53 activity detrimental to oxidative fibers, but not mitochondrial function or DNA repair 
activity crucial to preventing metabolic ROS damage. Furthermore, p53 is an established 
upregulator of immobilization-induced skeletal muscle atrophy [73]. Selective inhibition of this 
activity could explain why type I muscle fibers are resistant to sarcopenic wasting while type II 
fibers selectively undergo atrophy. It will be interesting to determine in future studies if co-
expression of SIRT1 and p53 selectively inhibit atrophy-related activity but not the DNA repair 
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functions, thereby ensuring that p53 cannot promote atrophy in oxidative fibers, where SIRT1 is 
highly expressed.  
2.5.9 Study limitations.  
The loss of older mice which died at old ages prior to conducting these studies, and 
removal of mice due to deteriorating health conditions at old ages limited the number of animals 
that were available to complete the experiments and therefore reduced the power of the study. 
The low number of older animals available for this study prevent us from obtaining mitochondrial 
measures in muscles after repair from CTX. The lower than ideal number of animals may also 
have contributed to several experiments which had significant differences in their global One-way 
ANOVA analyses but failed to detect significant between group differences. Due to the large effect 
sizes for some of the values calculated by the respective Cohen’s d statistics, the likelihood that 
some differences were masked by the sample size numbers is high. Increasing the power of these 
experiments and expanding the scope of the mitochondrial aspects of the study to include ROS 
production and mitochondrial respiration could potentially elucidate a secondary, external role of 
SIRT1 in modifying satellite cell viability through oxidative damage and/or mitochondrial 
dysfunction. 
2.5.10 Conclusions.  
The expression of SIRT1 in satellite cells is important for the functional development of 
skeletal muscle both initially and for full muscle regeneration. However, despite its functional 
significance in immature skeletal muscle, SIRT1 shows modest benefit on muscle mass or muscle 
function when it is expressed in the older skeletal muscle of C57BL6/j-background mice after 
acute injury. Our data suggest that there is little benefit for the physiological force or fatigue 
responses by overexpression of SIRT1 in vivo in the repaired older skeletal muscle of mice in the 
absence of any other interventions. However, SIRT1 may synergistically improve the effect of 
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beneficial proteins like p53 after injury, improving muscle adaptability and functionality. Ablation 
of basal SIRT1 expression in satellite cells, however, critically impacts future/mature muscle 
function, resulting in lower force production. The MCK-driven knockout of SIRT1 in the skeletal 
muscle of older mice showed an improved satellite cell dependent muscle regeneration potential, 
but this regeneration is possibly attenuated by the expression of p53 after muscle injury. Future 
work is needed to identify the synergistic effects between SIRT1 and p53 in muscle repair. We 
speculate that the beneficial effects produced by co-expression of SIRT1 and p53 may also 
underlie important mechanisms related to longevity, potentially including the mechanism behind 
type I fiber preservation during sarcopenia. 
2.6 Acknowledgments 
This project has been funded in part by the National Institutes of Health from the National Heart, 
Lung and Blood Institute grant HL128485 and the WVU CTSI grant U54GM104942, both awarded 
to JMH, and through funds from the University of Tennessee Health Science Center awarded to 
SEA. This work was also supported by the Community Foundation for the Ohio Valley and the 
Whipkey Trust, WV-INBRE (NIH grant P20 GM103434) to the Genomics Core Facility, and the 
WV Program to Stimulate Competitive Research (PSCoR). We would also like to acknowledge 
the West Virginia University Microscope Imaging Facility, which is supported by the Mary Babb 
Randolph Cancer Center and NIH grant P20 RR016440, P30 RR032138/GM103488, P20 
RR016477, and P20 GM109098. The antibodies BA-F8, SC-71 and BF-F3 were developed by 
Dr. S. Schiaffino. These antibodies were obtained from the Developmental Studies Hybridoma 
Bank developed under the auspices of the NICHD and maintained by The University of Iowa, 
Department of Biology, Iowa City, IA 52242. The authors certify that they comply with the ethical 
guidelines for authorship and publishing of the Journal of Cachexia, Sarcopenia and Muscle [74]. 
 
66 
 
 
2.7 Conflict of Interest 
Matthew J. Myers, Danielle L. Shepherd, Andrya J. Durr, David S. Stanton, Junaith S. 
Mohamed, John M. Hollander, and Stephen E. Alway declare that they have no conflict of 
interest.  
 
  
67 
 
2.8 REFERENCES 
 
1 Evans, W. J. What is sarcopenia? J Gerontol A Biol Sci Med Sci 50 Spec No, 5-8 
(1995). 
 
2 Cruz-Jentoft, A. J. et al. Prevalence of and interventions for sarcopenia in ageing adults: 
a systematic review. Report of the International Sarcopenia Initiative (EWGSOP and 
IWGS). Age Ageing (2014). 
 
3 Stenholm, S. et al. Sarcopenic obesity: definition, cause and consequences. Curr Opin 
Clin Nutr Metab Care 11, 693-700, doi:10.1097/MCO.0b013e328312c37d (2008). 
 
4 Alway, S. E., Mohamed, J. S. & Myers, M. J. Mitochondria Initiate and Regulate 
Sarcopenia. Exerc Sport Sci Rev 45, 58-69 (2017). 
 
5 Bua, E. A., McKiernan, S. H., Wanagat, J., McKenzie, D. & Aiken, J. M. Mitochondrial 
abnormalities are more frequent in muscles undergoing sarcopenia. J Appl Physiol 
(1985) 92, 2617-2624, doi:10.1152/japplphysiol.01102.2001 (2002). 
 
6 Thomsen, K. et al. Initial brain aging: heterogeneity of mitochondrial size is associated 
with decline in complex I-linked respiration in cortex and hippocampus. Neurobiol Aging 
61, 215-224, doi:10.1016/j.neurobiolaging.2017.08.004 (2018). 
 
7 Jarosz, J. et al. Changes in mitochondrial morphology and organization can enhance 
energy supply from mitochondrial oxidative phosphorylation in diabetic cardiomyopathy. 
Am J Physiol Cell Physiol 312, C190-C197, doi:10.1152/ajpcell.00298.2016 (2017). 
 
8 Marzetti, E. et al. Mitochondrial dysfunction and sarcopenia of aging: from signaling 
pathways to clinical trials. Int J Biochem.Cell Biol. 45, 2288-2301 (2013). 
 
9 Regmi, S. G., Rolland, S. G. & Conradt, B. Age-dependent changes in mitochondrial 
morphology and volume are not predictors of lifespan. Aging (Albany NY) 6, 118-130, 
doi:10.18632/aging.100639 (2014). 
 
10 Alway, S. E., MacDougall, J. D., Sale, D. G., Sutton, J. R. & McComas, A. J. Functional 
and structural adaptations in skeletal muscle of trained athletes. J Appl Physiol (1985) 
64, 1114-1120 (1988). 
 
11 Demontis, F., Piccirillo, R., Goldberg, A. L. & Perrimon, N. Mechanisms of skeletal 
muscle aging: insights from Drosophila and mammalian models. Dis Model Mech 6, 
1339-1352, doi:10.1242/dmm.012559 (2013). 
 
12 Lustgarten, M. S. et al. MnSOD deficiency results in elevated oxidative stress and 
decreased mitochondrial function but does not lead to muscle atrophy during aging. 
Aging Cell 10, 493-505, doi:10.1111/j.1474-9726.2011.00695.x (2011). 
 
13 Haigis, M. C. & Sinclair, D. A. Mammalian sirtuins: biological insights and disease 
relevance. Annu.Rev.Pathol. 5, 253-295 (2010). 
 
14 Houtkooper, R. H., Pirinen, E. & Auwerx, J. Sirtuins as regulators of metabolism and 
healthspan. Nat Rev Mol Cell Biol 13, 225-238, doi:10.1038/nrm3293 (2012). 
68 
 
15 Lee, D. & Goldberg, A. L. SIRT1 protein, by blocking the activities of transcription factors 
FoxO1 and FoxO3, inhibits muscle atrophy and promotes muscle growth. J Biol.Chem. 
288, 30515-30526 (2013). 
 
16 Brandon, A. E. et al. Overexpression of SIRT1 in rat skeletal muscle does not alter 
glucose induced insulin resistance. PLoS One 10, e0121959, 
doi:10.1371/journal.pone.0121959 (2015). 
 
17 Dugdale, H. F. et al. The role of resveratrol on skeletal muscle cell differentiation and 
myotube hypertrophy during glucose restriction. Mol Cell Biochem 444, 109-123, 
doi:10.1007/s11010-017-3236-1 (2018). 
 
18 Purushotham, A. et al. Hepatocyte-specific deletion of SIRT1 alters fatty acid 
metabolism and results in hepatic steatosis and inflammation. Cell Metab 9, 327-338, 
doi:10.1016/j.cmet.2009.02.006 (2009). 
 
19 Rasbach, K. A. et al. PGC-1alpha regulates a HIF2alpha-dependent switch in skeletal 
muscle fiber types. Proc Natl Acad Sci U S A 107, 21866-21871, 
doi:10.1073/pnas.1016089107 (2010). 
 
20 Canto, C. et al. AMPK regulates energy expenditure by modulating NAD+ metabolism 
and SIRT1 activity. Nature 458, 1056-1060 (2009). 
 
21 Nemoto, S., Fergusson, M. M. & Finkel, T. SIRT1 functionally interacts with the 
metabolic regulator and transcriptional coactivator PGC-1{alpha}. J Biol.Chem. 280, 
16456-16460 (2005). 
 
22 Philp, A. et al. Sirtuin 1 (SIRT1) deacetylase activity is not required for mitochondrial 
biogenesis or peroxisome proliferator activated receptor-{gamma} coactivator-1{alpha} 
(PGC-1{alpha}) deacetylation following endurance exercise. J Biol.Chem. 286, 30561-
30570 (2011). 
 
23 Conboy, I. M. & Rando, T. A. Aging, stem cells and tissue regeneration: lessons from 
muscle. Cell Cycle 4, 407-410 (2005). 
 
24 Brooks, M. J., Hajira, A., Mohamed, J. S. & Alway, S. E. Voluntary wheel running 
increases satellite cell abundance and improves recovery from disuse in gastrocnemius 
muscles from mice. J Appl Physiol (1985) 124, 1616-1628, 
doi:10.1152/japplphysiol.00451.2017 (2018). 
 
25 Hwang, A. B. & Brack, A. S. Muscle Stem Cells and Aging. Curr Top Dev Biol 126, 299-
322, doi:10.1016/bs.ctdb.2017.08.008 (2018). 
 
26 Day, K., Shefer, G., Shearer, A. & Yablonka-Reuveni, Z. The depletion of skeletal 
muscle satellite cells with age is concomitant with reduced capacity of single progenitors 
to produce reserve progeny. Dev Biol 340, 330-343 (2010). 
 
27 Alway, S. E. et al. Resveratrol enhances exercise-induced cellular and functional 
adaptations of skeletal muscle in older men and women. J Gerontol A Biol.Sci Med Sci 
72, 1595-1606, doi:10.1093/gerona/glx089 (2017). 
69 
 
28 Saini, A., Al-Shanti, N., Sharples, A. P. & Stewart, C. E. Sirtuin 1 regulates skeletal 
myoblast survival and enhances differentiation in the presence of resveratrol. Exp 
Physiol 97, 400-418, doi:10.1113/expphysiol.2011.061028 (2012). 
 
29 Ryall, J. G. et al. The NAD(+)-dependent SIRT1 deacetylase translates a metabolic 
switch into regulatory epigenetics in skeletal muscle stem cells. Cell Stem Cell 16, 171-
183, doi:10.1016/j.stem.2014.12.004 (2015). 
 
30 Shefer, G., Rauner, G., Yablonka-Reuveni, Z. & Benayahu, D. Reduced satellite cell 
numbers and myogenic capacity in aging can be alleviated by endurance exercise. 
PLoS.One. 5, e13307 (2010). 
 
31 Kwon, Y., Kim, J., Lee, C. Y. & Kim, H. Expression of SIRT1 and SIRT3 varies according 
to age in mice. Anat Cell Biol 48, 54-61, doi:10.5115/acb.2015.48.1.54 (2015). 
 
32 Jackson, J. R., Ryan, M. J. & Alway, S. E. Long-term supplementation with resveratrol 
alleviates oxidative stress but does not attenuate sarcopenia in aged mice. J Gerontol A 
Biol Sci Med Sci 66, 751-764 (2011). 
 
33 Del Campo, A. et al. Muscle function decline and mitochondria changes in middle age 
precede sarcopenia in mice. Aging (Albany NY) 10, 34-55, doi:10.18632/aging.101358 
(2018). 
 
34 Ohno, Y. et al. Suppression of Myostatin Stimulates Regenerative Potential of Injured 
Antigravitational Soleus Muscle in Mice under Unloading Condition. Int J Med Sci 13, 
680-685, doi:10.7150/ijms.16267 (2016). 
 
35 Bloemberg, D. & Quadrilatero, J. Rapid determination of myosin heavy chain expression 
in rat, mouse, and human skeletal muscle using multicolor immunofluorescence 
analysis. PLoS One 7, e35273, doi:10.1371/journal.pone.0035273 (2012). 
 
36 Pasut, A. et al. Notch Signaling Rescues Loss of Satellite Cells Lacking Pax7 and 
Promotes Brown Adipogenic Differentiation. Cell Rep 16, 333-343, 
doi:10.1016/j.celrep.2016.06.001 (2016). 
 
37 Liu, L., Cheung, T. H., Charville, G. W. & Rando, T. A. Isolation of skeletal muscle stem 
cells by fluorescence-activated cell sorting. Nat Protoc 10, 1612-1624, 
doi:10.1038/nprot.2015.110 (2015). 
 
38 Mohamed, J. S., Wilson, J. C., Myers, M. J., Sisson, K. J. & Alway, S. E. Dysregulation 
of SIRT-1 in aging mice increases skeletal muscle fatigue by a PARP-1-dependent 
mechanism. Aging (Albany NY) 10, 820-834 (2014). 
 
39 Rothermel, B. et al. A protein encoded within the Down syndrome critical region is 
enriched in striated muscles and inhibits calcineurin signaling. J Biol Chem 275, 8719-
8725 (2000). 
 
40 Siu, P. M., Pistilli, E. E., Butler, D. C. & Alway, S. E. Aging influences cellular and 
molecular responses of apoptosis to skeletal muscle unloading. Am J Physiol Cell 
Physiol 288, C338-C349 (2005). 
70 
 
41 Haramizu, S. et al. Dietary resveratrol confers apoptotic resistance to oxidative stress in 
myoblasts. J Nutr Biochem 50, 103-115, doi:10.1016/j.jnutbio.2017.08.008 (2017). 
 
42 Takahashi, H. et al. Epigallocatechin-3-gallate increases autophagy signaling in resting 
and unloaded plantaris muscles but selectively suppresses autophagy protein 
abundance in reloaded muscles of aged rats. Exp Gerontol 92, 56-66, 
doi:10.1016/j.exger.2017.02.075 (2017). 
 
43 Croston, T. L. et al. Functional deficiencies of subsarcolemmal mitochondria in the type 
2 diabetic human heart. Am J Physiol Heart Circ Physiol 307, H54-65, 
doi:10.1152/ajpheart.00845.2013 (2014). 
 
44 Dabkowski, E. R. et al. Diabetic cardiomyopathy-associated dysfunction in spatially 
distinct mitochondrial subpopulations. Am.J.Physiol.Heart.Circ.Physiol. 296, H359-H369 
(2009). 
 
45 Nichols, C. E. et al. Cardiac and mitochondrial dysfunction following acute pulmonary 
exposure to mountaintop removal mining particulate matter. Am J Physiol Heart Circ 
Physiol 309, H2017-2030, doi:10.1152/ajpheart.00353.2015 (2015). 
 
46 Ryan, M. J., Jackson, J. R., Hao, Y., Leonard, S. S. & Alway, S. E. Inhibition of xanthine 
oxidase reduces oxidative stress and improves skeletal muscle function in response to 
electrically stimulated isometric contractions in aged mice. Free Radic Biol Med 51, 38-
52, doi:10.1016/j.freeradbiomed.2011.04.002 (2011). 
 
47 Wang, Y., Mohamed, J. S. & Alway, S. E. M-cadherin-inhibited phosphorylation of B-
catenin augments differentiation of mouse myoblasts. Cell Tissue Res 351, 183-200 
(2013). 
 
48 Suwa, M., Nakano, H., Radak, Z. & Kumagai, S. Endurance exercise increases the 
SIRT1 and peroxisome proliferator-activated receptor gamma coactivator-1alpha protein 
expressions in rat skeletal muscle. Metabolism 57, 986-998 (2008). 
 
49 Nilwik, R. et al. The decline in skeletal muscle mass with aging is mainly attributed to a 
reduction in type II muscle fiber size. Exp.Gerontol. 48, 492-498 (2013). 
 
50 Chalkiadaki, A., Igarashi, M., Nasamu, A. S., Knezevic, J. & Guarente, L. Muscle-
specific SIRT1 gain-of-function increases slow-twitch fibers and ameliorates 
pathophysiology in a mouse model of duchenne muscular dystrophy. PLoS.Genet. 10, 
e1004490 (2014). 
 
51 Rodgers, J. T., Lerin, C., Gerhart-Hines, Z. & Puigserver, P. Metabolic adaptations 
through the PGC-1 alpha and SIRT1 pathways. FEBS Lett. 582, 46-53 (2008). 
 
52 Sousa-Victor, P. & Munoz-Canoves, P. Regenerative decline of stem cells in sarcopenia. 
Mol Aspects Med 50, 109-117 (2016). 
 
53 Herbst, A. et al. Accumulation of mitochondrial DNA deletion mutations in aged muscle 
fibers: evidence for a causal role in muscle fiber loss. J Gerontol.A Biol.Sci.Med.Sci. 62, 
235-245 (2007). 
71 
 
54 Williamson, C. L. et al. Enhanced apoptotic propensity in diabetic cardiac mitochondria: 
influence of subcellular spatial location. Am J Physiol Heart Circ Physiol 298, H633-
H642 (2010). 
 
55 Parihar, M. S. & Brewer, G. J. Simultaneous age-related depolarization of mitochondrial 
membrane potential and increased mitochondrial reactive oxygen species production 
correlate with age-related glutamate excitotoxicity in rat hippocampal neurons. J 
Neurosci Res 85, 1018-1032, doi:10.1002/jnr.21218 (2007). 
 
56 Canto, C. & Auwerx, J. Caloric restriction, SIRT1 and longevity. Trends Endocrinol 
Metab 20, 325-331, doi:10.1016/j.tem.2009.03.008 (2009). 
 
57 Hughes, D. C. et al. Age-related Differences in Dystrophin: Impact on Force Transfer 
Proteins, Membrane Integrity, and Neuromuscular Junction Stability. J Gerontol A Biol 
Sci Med Sci 72, 640-648, doi:10.1093/gerona/glw109 (2017). 
 
58 Picca, A. et al. Circulating Mitochondrial DNA at the Crossroads of Mitochondrial 
Dysfunction and Inflammation During Aging and Muscle Wasting Disorders. 
Rejuvenation Res 21, 350-359, doi:10.1089/rej.2017.1989 (2018). 
 
59 Amat, R. et al. SIRT1 controls the transcription of the peroxisome proliferator-activated 
receptor-gamma Co-activator-1alpha (PGC-1alpha) gene in skeletal muscle through the 
PGC-1alpha autoregulatory loop and interaction with MyoD. J Biol Chem 284, 21872-
21880, doi:10.1074/jbc.M109.022749 (2009). 
 
60 Marzetti, E. et al. Role of mitochondrial dysfunction and altered autophagy in 
cardiovascular aging and disease: from mechanisms to therapeutics. Am.J Physiol Heart 
Circ.Physiol 305, H459-H476 (2013). 
 
61 Sun, N., Youle, R. J. & Finkel, T. The Mitochondrial Basis of Aging. Mol Cell 61, 654-
666, doi:10.1016/j.molcel.2016.01.028 (2016). 
 
62 Seo, D. Y. et al. Age-related changes in skeletal muscle mitochondria: the role of 
exercise. Integr Med Res 5, 182-186, doi:10.1016/j.imr.2016.07.003 (2016). 
 
63 Braidy, N. et al. Age related changes in NAD+ metabolism oxidative stress and Sirt1 
activity in wistar rats. PLoS One 6, e19194, doi:10.1371/journal.pone.0019194 (2011). 
 
64 Jang, S. Y., Kang, H. T. & Hwang, E. S. Nicotinamide-induced mitophagy: event 
mediated by high NAD+/NADH ratio and SIRT1 protein activation. J Biol Chem 287, 
19304-19314, doi:10.1074/jbc.M112.363747 (2012). 
 
65 Song, S. B. et al. Modulation of Mitochondrial Membrane Potential and ROS Generation 
by Nicotinamide in a Manner Independent of SIRT1 and Mitophagy. Mol Cells 40, 503-
514, doi:10.14348/molcells.2017.0081 (2017). 
 
66 Williams, A. B. & Schumacher, B. p53 in the DNA-Damage-Repair Process. Cold Spring 
Harb Perspect Med 6, doi:10.1101/cshperspect.a026070 (2016). 
 
67 Bartlett, J. D., Close, G. L., Drust, B. & Morton, J. P. The emerging role of p53 in 
exercise metabolism. Sports Med 44, 303-309, doi:10.1007/s40279-013-0127-9 (2014). 
72 
 
 
68 Pala, F. et al. Distinct metabolic states govern skeletal muscle stem cell fates during 
prenatal and postnatal myogenesis. J Cell Sci 131, doi:10.1242/jcs.212977 (2018). 
 
69 Siu, P. M. & Alway, S. E. Subcellular responses of p53 and Id2 in fast and slow skeletal 
muscle in response to stretch-induced overload. J Appl Physiol (1985) 99, 1897-1904, 
doi:10.1152/japplphysiol.00374.2005 (2005). 
 
70 Porrello, A. et al. p53 regulates myogenesis by triggering the differentiation activity of 
pRb. J Cell Biol 151, 1295-1304 (2000). 
 
71 Alway, S. E., Hughson, R. L., Green, H. J., Patla, A. E. & Frank, J. S. Twitch potentiation 
after fatiguing exercise in man. Eur J Appl Physiol 56, 461-466 (1987). 
 
72 Lorenz, D. Postactivation potentiation: an introduction. Int J Sports Phys Ther 6, 234-240 
(2011). 
 
73 Siu, P. M. & Alway, S. E. Id2 and p53 participate in apoptosis during unloading-induced 
muscle atrophy. Am J Physiol Cell Physiol 288, C1058-C1073 (2005). 
 
74 von Haehling, S., Morley, J. E., Coats, A. J. S. & Anker, S. D. Ethical guidelines for 
publishing in the journal of cachexia, sarcopenia and muscle: update 2017. J Cachexia 
Sarcopenia Muscle 8, 1081-1083, doi:10.1002/jcsm.12261 (2017). 
 
 
 
  
73 
 
2.9 Figure Legends 
2.9.1 Figure 1
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2.9.2 Figure 1. Protein expression in young wild-type and older variant SIRT1 expressing 
mice. (A). SIRT1 protein expression collected from 12-week-old wild-type (WT), overexpressor 
(OE), satellite cell knockout (SKO) and skeletal muscle knockout (MKO) mice prior to and 2 hours 
after exercise (-ex). (B). Densitometric and immunoblot analysis of SIRT1 protein expression 
measured in young wild-type (YWT, n=3) and older (80+ weeks) wild-type (WT-80, n=3), SIRT1 
overexpressor (OE-80, n=3), SIRT1 skeletal muscle knockout (MKO-80, n=3), and SIRT1 satellite 
cell knockout (SKO-80, n=3) mice hind limbs 21 days after phosphate buffered saline (PBS) or 
cardiotoxin (CTX) injection. Basal SKO-80 SIRT1 expression was significantly reduced relative to 
YWT mice (*P < 0.05), while OE-80 PBS SIRT1 expression was significantly increased (***P < 
0.001) relative to YWT PBS. Only SKO-80 mice showed a significant increase in SIRT1 
abundance for CTX injected muscles relative to their own PBS injected hind limbs (†P < 0.05). 
(C). Representative immunoblots of SIRT1 downstream targets FoxO3a and p53 and loading 
control GAPDH for SIRT1 variant expressers after PBS/CTX injection and recovery. 
Densitometric analysis of the immunoblots revealed no significant differences in protein 
expression. (D). Densitometric analysis of the immunoblots revealed significant differences in the 
abundance of p53 protein for OE-80 CTX (###P < 0.001) and MKO-80 CTX (#P < 0.05) groups 
relative to YWT CTX mice. (E). Representative immunoprecipitation immunoblots for SIRT1 
downstream target PGC1α and its acetylation state. (F). Densitometric analysis of relative PGC1α 
acetylation. No significant difference was discovered between groups versus the YWT control 
when using one-way ANOVA with corrections for multiple comparisons. 
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2.9.3 Figure 2
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2.9.4 Figure 2. The effects of SIRT1 expression on hindlimb skeletal muscle function in 
young wild-type and older mice. Young wild-type (YWT, 20-30 weeks, n=8) and older (80+ 
weeks) wild-type (WT-80, n=8), SIRT1 overexpressor (OE-80, n=9), SIRT1 skeletal muscle 
knockout (MKO-80, n=7), and SIRT1 satellite cell knockout (SKO-80, n=4) mice were 
anesthetized with 2-3% isoflurane and electrically stimulated once at 75Hz (A, B) and 180 times 
at 40Hz (C-P) to produce muscle contractions (pre-treatment, PRE) prior to injection with snake 
cardiotoxin (CTX) and vehicle control (PBS).  21 days post-injection, muscle force was 
reexamined. Data are presented as the mean force at 75Hz ± SD (***P<0.01; †P < 0.05) (* 
denotes a significant difference from the YWT control, † denotes a significant difference between 
a genotype’s control and treatment). B. Force recovery was measured by normalizing PBS/CTX 
data to the same limb pre-treatment. Data presented as fold change ± SD.  C. Comparison of all 
and individual (C-H) fatigue profiles for experimental groups normalized to earliest maximum 
force. Data are presented as fold change (†P < 0.05, ††P<0.01, †††P<0.01, ††††P<0.001). 
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2.9.5 Figure 3 
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2.9.6 Figure 3. The effects of SIRT1 expression on hindlimb skeletal muscle structure in 
young wild-type and older mice (A-E). Gastrocnemius and soleus muscles for YWT (A), WT-80 
(B), OE-80 (C), MKO-80 (D), and SKO-80 (E), were dissected after physiological evaluation and 
flash frozen in methyl-butane chilled by liquid nitrogen. Cross sections were cut at 16μm and 
stained for MHC I (green) or MHC IIa/b and dystrophin (red), then mounted with DAPI hardset 
(blue). Total cross-sectional area of gastrocnemius cross-sections (F), soleus cross sections (G), 
and type I fiber cross sections (H), were calculated by fiber tracing with the ImageJ software 
package on images captured at 4x resolution. Data are presented as mean ± SD compared to 
YWT PBS, (n=3). [F*] denotes that a significant difference was observed for the global One-way 
ANOVA tests, but not for specific comparisons. I. The gastrocnemius type I percentage was 
calculated by dividing the summed type I fiber CSA for each section by the total CSA of the 
respective gastrocnemius (n=3). Scale bar = 100 m. 
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2.9.7 Figure 4 
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2.9.8 Figure 4. The effects of SIRT1 expression on cell replication in older murine skeletal 
muscle after recovery from injury. A-D. Tibialis anterior (TA) cross-sections were taken for WT-
80 (A), OE-80 (B), MKO-80 (C), and SKO-80 (D) mice 21 days after CTX injury at 4x resolution. 
Sections were stained against BrdU (green, indicated by white arrows) and dystrophin (red). E. 
Total CSAs of TA cross-sections were calculated and presented as mean CSA (μm2) ± SD (n=3). 
F. BrdU positive nuclei (A-D) were quantified and normalized to their respective TA CSA. Data 
are presented as mean ± SD (n=3); (*P < 0.05). Scale bar = 100 m 
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2.9.9 Figure 5 
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2.9.10 Figure 5. The effects of SIRT1 expression on satellite cell proliferation in older murine 
skeletal muscle.   (A-D). EdU+ cells were identified from FACS-isolated satellite cell populations 
from TA muscles of WT-80 (A), OE-80 (B), MKO-80 (C), and SKO-80 (D) mice. (E). The 
proliferation factor was determined by the total of EdU+ cells counted from 9 fields, normalized to 
the total number of cells in the plate. Experiments were repeated in triplicate and data are 
presented as mean ± SD (n=3); (*P < 0.05). 
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2.9.11 Figure 6 
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2.9.12 Figure 6. Characteristics of mitochondria in young wild-type and older SIRT1-
expression models of murine skeletal muscle.   Plantar flexor muscle groups (gastrocnemius, 
soleus, and plantaris) were obtained from YWT and older SIRT1-expressor mice prior to isolation 
of IFM and SSM subpopulations.  Significant differences were found in the sizes of older 
mitochondria relative to YWT mitochondria for both SSM (A) and IFM (D). No significant 
differences were found for specific comparisons of internal complexity in SSM (B) or in IFM (E). 
OE-80 showed a significantly lower mitochondrial membrane potential (ΔΨm) than YWT mice 
mitochondria as reflected in the lower ratio of orange/green mitochondria relative to YWT in SSM 
(C) and IFM (D) [F*]. MKO-80 mice and OE-80 mice show the potential for having inversely 
affected ΔΨm (F). The shift from green to orange occurs as the JC-1 dye forms aggregates upon 
membrane polarization causing shifts in emitted light from 530 nm (green) to 590 nm (orange). 
Addition of 200 µM dinitrophenol, which collapses the ΔΨm was used as an assay control. Data 
are expressed as the mean orange fluorescence divided by the mean green fluorescence of 
20,000 mitochondrial events per individual mitochondrial sample.  The activity for mitochondrial 
electron transport chain complexes was calculated for SSM (G-J) and IFM (K-N). OWT-80 
showed increased complex III activity in SSM (H), while OE-80 mice showed decreased ATP 
synthase activity (J). Complex IV activity is depressed in older WT and OE models in SSM, but 
not SIRT1 knockout models (I). Data are presented as mean ± SD (n=5). (*P < 0.05, **P < 0.01, 
***P < 0.001). [F*] denotes that a significant difference was observed for the global one-way 
ANOVA tests, but not for specific comparisons.  
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Table 1: Characteristics of Study Animals 
 
 
YWT OWT OE MKO SKO 
Age (Weeks) 24.8 ± 0.7 83.7 ± 0.5 86.9 ± 1.5 90.1 ± 2.9 84.2 ± 4.2 
Mass (g) - Total 28.4 ± 1.4 35.8 ± 2.1 31.7 ± 0.8 34.9 ± 1.5 31.2 ± 1.7 
Mass (g) - Males 32.1 ± 1.1* 37.3 ± 2.6 32.7 ± 0.7 34.9 ± 2.0 34.5 ± 2.1 
Mass (g) - Female 24.0 ± 0.9* 33.5 ± 3.6 29.6 ± 1.7 34.8 ± 2.5 31.4 ± 2.1 
%Male 53.9% 61.6% 66. 7% 58.3% 30% 
%Female 46.2% 38.5% 33.3% 41. 7% 70% 
n 13 13 14 12 10 
 
Mass of each group was recorded immediately prior to euthanasia. Experimental groups 
consisted of randomly distributed males and females.  Young wild type (YWT) males differed 
significantly in body mass only from YWT females (*P < 0.05). Data are expressed as means ± 
SD. 
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Chapter 3: 
Discussion 
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3.1. Summary 
The primary objectives of this investigation were to (1) elucidate the role of SIRT1 in 
regulating muscle function and fatigue resistance in regenerating skeletal muscle of aged mice, 
(2) determine the role of SIRT1 in regulating mitochondrial biogenesis and function in 
regenerating aging skeletal muscle, and (3) determine if SIRT1 activation can improve 
proliferation in satellite cells in aging. The long-term goal of this study was to determine the 
physiological relevance of SIRT1 expression in the functionality of aging skeletal muscle and 
provide insight as to whether SIRT1 is an effective therapeutic target for interventions designed 
to treat or prevent muscle wasting with age. The central hypothesis of this dissertation was that 
overexpression of the protein SIRT1 would provide protective benefits from functional muscle loss 
accompanying aging and that SIRT1 expression would act to promote longevity in skeletal muscle 
by improving mitochondrial health and increasing the proliferation of muscle satellite cell 
proliferation after injury. Our rationale for the proposed research was that SIRT1 has been 
strongly linked to longevity, that type I skeletal muscle fibers both resist sarcopenic muscle 
wasting with age and highly express the protein SIRT1, and that SIRT1 is a known up-stream 
regulator of mitochondria—whose dysfunction has been long linked to aging [1,2]—through the 
PGC-1α axis [3].  
In this dissertation, we demonstrated that in aged, non-sarcopenic mice, hindlimb muscle 
function is not affected by the abundance of SIRT1 in adult skeletal muscle, although major 
reductions in contraction force can be seen if SIRT1 is absent from muscle satellite cells in aged 
mice. Young, wild-type mice showed impaired strength recovery after recovery from CTX-induced 
injury, though this difference was not seen in aged mice of any genotype. (This finding may be 
explained in part by the [F*] seen in our data for the CSA of the YWT mice—although we did not 
show significant differences, the CSA of YWT mice post-CTX recovery indicated that the soleus 
muscles of young mice did not recover to their full size. Secondly, because it was difficult to detect 
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significant reductions in muscle cross sectional area for the aged models, the older mice may 
have possessed enough increased oxidative stress in their muscles associated with aging to 
promote further muscle repair while not possessing enough stress to impair muscle functionality.)  
Neither the presence nor absence of SIRT1 affected fatigue resistance in the hindlimbs of un-
injured, aged mice. Interestingly, both the muscle knockout and overexpressor models of SIRT1 
showed improved fatigue resistance relative to baseline fatigability, with the SIRT1 overexpressor 
model’s force profile suggesting the muscles underwent postactivation potentiation—an increase 
in muscle force during low frequency activation (for example, during endurance exercise) 
following a conditioning activity, such that a previous muscle contractions improves the following 
contraction [4]. 
Next, we showed that very few differences occurred in the mitochondria between different 
genotypical models of SIRT1 expression in aged mice compared to the young wild-type controls. 
Although mitochondria tended to be significantly larger in aged mouse models relative to the 
young, wild-type controls, the models showed very little variability in number, internal complexity, 
mitochondrial membrane potential, or mitochondrial complex activity. Although this data was 
surprising based on our initial expectations, the accrual of recent literature has begun to suggest 
that the intercellular levels of [NAD+] and its enzymatic regulators are more important to the pro-
longevity functions associated with SIRT1 than actual SIRT1 abundance [5–7]. Also surprising 
was that despite expecting to find an increase in mitochondrial complex activity, mitochondrial 
membrane potential, and mitochondrial population in the mitochondria from our aged 
overexpressor model, our data suggested that ΔΨm and the activity of complex IV and ATP-
synthase were instead blunted with the overexpression of SIRT1, a visible difference and trend 
relative to the other transgenic models we investigated.  
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Finally, we showed that the loss of SIRT1 in adult skeletal muscle, rather than the 
overexpression of SIRT1, improved early proliferation of satellite cells, although this effect 
appeared to be attenuated somewhat later in the process of regeneration.  
Overall, the importance of SIRT1 in the skeletal muscle of aged mice is largely dependent 
on its abundance in muscle satellite cells, rather than in adult skeletal muscle. Furthermore, even 
the large boost in satellite cell proliferation seen in the skeletal muscle knockout model of SIRT1 
appears to have very little effect on muscle function. Surprisingly, it seems that a disruption in 
SIRT1 activity in aged skeletal muscle improves the fatigue resistance of the muscle after 
recovery from injury, regardless of whether the muscle has an increase or loss of function, 
indicating that SIRT1 may be a secondary or tertiary regulator for muscle function after injury. 
Interestingly, the injury-recovery models that showed an improvement in their fatigabilities also 
showed an increased abundance of the protein p53, a downstream target of SIRT1. Thus, 
although our current evidence indicates altering SIRT1 abundance should not be a primary focus 
for interventions against muscle loss associated with aging, the investigation of SIRT1’s 
relationship with p53 in the process of muscle repair is an important next step in understanding 
the aging of skeletal muscle. 
3.2. General Discussion 
Despite the many studies examining the expression of SIRT1 in various models of aging 
[8], few have focused on the translational effects of SIRT1 expression in muscle to functional 
relevance [9]. Our data show interesting and novel insights regarding SIRT1’s effect on hindlimb 
muscle function in aged and injured mouse models. However, some data seemingly conflict with 
previous studies, especially in the context of muscle fiber structure and composition. Earlier 
studies from the Guarente lab have shown that overexpression of SIRT1 could rescue mice from 
the phenotype of Duchenne’s muscular dystrophy and shift the fiber-type distribution toward 
oxidative fibers [10]. These findings were strengthened by studies showing that overexpression 
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of PGC-1α, a downstream target of SIRT1 regulation, and resveratrol, a known activator of SIRT1 
[11], produced a similar rescue of dystrophic function and fiber-type shift [12,13]. These conflicts 
may arise from the degree of dysfunction in the dystrophic phenotype, as SIRT1 transgenic mice 
have also been shown to have distinctly similar muscle characteristics compared to wild-type mice 
in several studies, including size and weight [7,10,14]. Furthermore, the loss of dystrophin has 
been shown to affect the structural integrity of satellite cells during regeneration by dysregulating 
scaffold formation, a contributing phenotypical difference not present in the non-dystrophic 
C57BL/6J background mice [15]. 
Although our study only takes a shallow look into the make-up of the gastrocnemius, 
soleus, and tibialis anterior muscles of the mouse hindlimb, we have shown no significant 
difference in muscle fiber cross sectional area or fiber-type composition between the SIRT1 
models. One explanation for this mismatch is the power of our statistical analysis. Analysis of the 
cross-sectional areas (CSAs) of fiber types revealed significant differences did exist between 
groups when assessed by two-way ANOVA with corrections for multiple comparisons against the 
YWT control, but significance could not be established between specific groups, likely due to a 
masking effect, as indicated by the large effect sizes calculated for the Cohen’s d statistic. 
Although it is possible to infer from the data that the CSA of gastrocnemius muscles is decreased 
in aged wild-type mice, but is possibly rescued by altering the expression of SIRT1, these results 
cannot be confirmed by our current data. However, the total cross-sectional area attributed to type 
I fibers in the gastrocnemius muscles does stay consistent among the models, indicating that 
altering SIRT1 expression levels alone does not seem to influence the relative make-up of mixed-
fiber muscles.  
Along with the small differences detected in the muscle structure, we also reported few 
differences between the majority of the transgenic models in respect to mitochondrial complexity, 
population, and complex activity. These findings suggest that SIRT1’s role in promoting longevity 
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or a caloric-restriction phenotype likely requires very little expression of the protein itself, and is 
more dependent on an outside activator. Recent literature has indicated that SIRT1 
overexpression models show significantly different genetic profiles compared to caloric restriction 
or exercise trained mice, and possess different mitochondrial functionality compared to such 
models, characterized by lower rates of mitochondrial respiration and lower glucose clearance 
[7]. These findings are supported by studies showing the vast effectiveness of supplementation 
of NAD+ conjugates, such as nicotinamide riboside, in promoting cellular longevity [5] and pro-
longevity factors, such as increased mitophagy, lower blood glucose levels, and muscle stem cell 
population [16,17] 
In other aspects, however, our data reflect the findings in studies using similar models; for 
example, literature has reported that the muscle creatine kinase-knockout model of SIRT1 (MKO) 
shows that loss of SIRT1 activity does not affect oxidative metabolism or myofiber composition in 
skeletal muscle [10]. Furthermore, their MKO model also showed no difference from WT mice in 
fatigability under more mild exercise training. An important caveat is that dystrophic mice suffer 
from structural weakness due to a dysfunctional dystrophin protein; furthermore, affected muscle 
in these cases are susceptible to contraction-induced rupture of the sarcolemma [12] and often 
present many fibers with centrally-located nuclei [10], a phenotypical sign of muscle damage. Our 
data may shed some light on how SIRT1 overexpression rescues muscle function, as our work 
has shown that after injury, in models where the protein p53 is significantly increased in recovered 
muscle, resistance to fatigue is improved; moreover, co-expression of the SIRT1 overexpressed 
protein and p53 show signs of muscle potentiation, improving the force output for fatigue 
contractions in the early stages of the exercise protocol.  
The protein p53 is a highly studied gene, important to cancer research, that encodes a 
transcription-regulating protein with wide effects on cellular biology, most notably its ability to 
promote cell cycle arrest and apoptosis [18]. The ability of p53 to induce cell cycle arrest may also 
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function as a stop-gap in which p53 can act to promote DNA damage repair, as recent evidence 
continues to link the protein to several DNA-repair pathways [19]. Curiously, our data indicates 
that p53 shows an increase in abundance in both the MKO and OE aged models after injury, 
hinting that SIRT1 dysregulation may lead to increased protein expression of p53 through multiple 
regulatory pathways or by altogether different means. A possible explanation for the MKO model 
is that in the absence of SIRT1, which promotes the mitochondrial regulatory activity of PGC-1α 
including stimulating biogenesis and upregulating the antioxidant proteins that manage oxidative 
phosphorylation, CTX-induced muscle damage coupled with more overall oxidative stress (from 
the lower abundance of antioxidants) could cause the stimulation of p53 transcription/translation 
to rise as a compensatory mechanism. Because a loss of SIRT1 would also reduce inhibition of 
the SIRT1 target NF-κB, an inducer of the inflammatory response and inhibitor of p53, increased 
NF-κB could be potentially inhibiting the apoptotic-functions of p53 [20,21]. Thus, only the DNA 
repair pathways mediated by p53 after CTX-injury might be activated and could therefore account 
for the improved fatigue resistance in MKO mice. Alternatively, our data indicate that the loss of 
SIRT1 abundance in adult skeletal muscle promotes early proliferation of satellite cells as 
determined by EdU staining in vitro, with an apparent attenuation of activity after 21 days as 
determined by BrdU staining in vivo. These assays also indicate the attenuation of satellite cell 
proliferation in the OE-80 and SKO-80 models relative to proliferation in WT-80 mice, which 
strongly suggests the upregulation of SIRT1 during the process of skeletal muscle differentiation 
inhibits satellite cell proliferation. This data is supported by Ryall et al. [22], who showed that 
SIRT1 protein expression correlating with the oxidative metabolic state of quiescent satellite cells 
acts to inhibit their activation—whereas downregulation of SIRT1 in satellite cells promotes a 
metabolic switch to glycolysis and subsequent activation of these cells. Thus, the down-regulation 
of SIRT1 prior to satellite cell activation and up-regulation of SIRT1 during differentiation may be 
part of a metabolic signal within the muscle that controls satellite cell activity. This would indicate 
a pathway possibly independent of p53, wherein the MKO-80 model’s improved muscle 
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performance after hindlimb injury and repair stems from improved muscle satellite cell 
proliferation.  
 Conversely in the OE models, p53 recruited after injury may be more effectively enhanced 
by SIRT1 overexpression, which acts to directly bind and deacetylate p53 to inhibit its apoptotic 
functions by blockings its translocation to the nucleus [22]. Blocking p53’s access to the nucleus 
may therefore promote translocation of p53 to mitochondria, where it can act to form mitochondrial 
DNA complexes [23]. Because previous studies have shown that p53 expression can improve 
endurance exercise capacity [24] it may likely be through this mechanism that p53 upregulation 
correlates with improved endurance exercise capability in the OE model after injury. Research 
published by Zhao et al. have shown that prior to apoptosis, p53 translocates to the mitochondria 
where it targets the manganese-dependent superoxide dismutase (MnSOD) [25]. Subsequently, 
the loss of MnSOD’s superoxide scavenging activity results in an increase of oxidative stress in 
the mitochondria was associated with a drop in ΔΨm. These findings reflect the data we reported 
for the mitochondrial membrane potential and complex activities, wherein the ΔΨm and activities 
were similar for most of the SIRT1 transgenic models, except for the OE-80 model which showed 
a trend for decreased ΔΨm and complex IV and ATP synthase activity. Furthermore, our data 
suggest a masked significant decrease for the mitochondrial abundance of the OE-80 model 
relative to the control model (Fig. 1). Taken together, these findings indicate that increased SIRT1 
abundance from overexpression may be interacting with increased levels of p53 stimulated by 
muscle injury to redirect p53 from the nucleus to the mitochondria. In cases of cellular stress, 
SIRT1 has been shown to promote cellular protection by inhibiting the apoptotic capabilities of 
the FOXO proteins, which share somewhat similar functions with p53, while improving their DNA 
repair capability in cells chemically stressed by H2O2 [26]. This process likely results from partial 
deacetylation (and therefore, only partial deactivation) of the FOXO/p53 transcription factors; 
indeed, p53 is known to be a target of both the SIRT1 and PID/HDAC1 deacetylases [22] that can 
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alter its translocation targets. This possibility is supported by recent literature reporting that p53 
localization to the mitochondria helps to adapt the mitochondria to endurance exercise training, 
an effect which is attenuated in muscle knockout models of SIRT1 [14]. Furthermore, these 
models indicated p53 possesses some sort of regulatory function for mitochondrial autophagy—
in the absence of p53, autophagy signaling was increased, but clearance of autophagosomes 
was impaired. Taken altogether, a possible explanation for our data is that the abundance of 
SIRT1 in the aged overexpressor model interacts with p53 after muscle injury to promote 
mitochondrial health by inducing translocation of p53 to the mitochondria, where it promotes 
mitochondrial housekeeping functions. 
3.3. Future Directions 
Although the idea behind this mechanism comes from several established studies, further 
investigation is required to test and verify the veracity of the beneficial effects of SIRT1 and p53 
co-expression in skeletal muscle. Future studies could focus on models with alternate levels of 
p53 expression, much like the various SIRT1 mouse models employed in this dissertation. 
Alternatively, experiments focusing on the overexpression of SIRT1 and p53 both independently 
and under co-expression in mouse models treated with exercise and/or injury would be a first step 
in deriving a mechanism by which these proteins interact. 
Another point to expand upon for future studies is examining how metabolic interventions 
affect SIRT1’s and/or p53’s roles in muscle repair after injury. Caloric restriction has long been 
linked to SIRT1 and is often employed as an activator of SIRT1 activity [8]. It is possibly that the 
muscle structure for our SIRT1 OE mice did not show significant differences from WT mice 
because the SIRT1 was not entirely activated, despite being overexpressed. Our initial 
experimental design included a component to include caloric intake as a variable, but budgetary 
and physical restraints related to the housing cost of animals and the ability to accurately assess 
obese mouse hindlimb function (obese mice were too large to fit in our dynamometer set-up and 
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thus their muscle function could not be accurately assessed) prohibited the inclusion of these 
variables. Thus, examining the physiological effects of caloric restriction or diet-induced obesity 
on the muscle function in these variant SIRT1 expressing mouse models could further elucidate 
the role of SIRT1 in muscle function. These data could prove interesting, given that SIRT1 
overexpression appeared to work synergistically with p53 expression to promote increased 
fatigue resistance in muscle recovered from CTX-induced injury despite the absence of a 
secondary intervention designed to activate SIRT1 activity.  
Finally, another set of future experiments could focus on understanding the role of SIRT1 
in muscle fiber development during the formation of new fibers from muscle satellite cells. 
Although a paper published from the Sartorelli lab by Ryall et al [27] suggest that the lack of SIRT1 
in early muscle satellite cells causes premature differentiation of the satellite cells into 
dysfunctional and deformed muscle fibers, some discrepancies within the model still exist. 
Specifically, both our data and data published by the Ryall study seem to indicate that in the Pax7-
promoter driven muscle satellite cell knockout of SIRT1, SIRT1 expression is still ablated in adult 
skeletal muscle. However, Pax7 is only expressed in quiescent satellite cells, so SIRT1 should 
theoretically be expressed at or near the level of SIRT1 in of wild-type mice in skeletal muscle 
where the Pax7 promoter is no longer active. Establishing the role of SIRT1 and its importance in 
the various steps of the metabolic regulation of muscle satellite cells during proliferation and/or 
differentiation could further elucidate the results seen in our data and help to establish a timeline 
for the importance of SIRT1 expression in the regulation of satellite cell differentiation and nascent 
fiber formation. These studies could be further supported with a complementary genetic 
conditional knockout model combining the MKO-cre and Pax7-cre mice (crossed with SIRT1-
floxed mice) to create a SIRT1 knockout model with continuous ablation of SIRT1 from the satellite 
cell to the fully formed muscle fiber. This proposed study would be important in determining where 
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SIRT1 shifts from being necessary for normal function to being non-critical, but beneficial to 
muscle repair. 
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3.5 Figures & Figure Legends 
3.5.1. Figure 1. 
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3.5.2. Figure 1. Mitochondrial abundance among SIRT1 transgenic mouse models. 
Mitochondria were isolated and then quantified with a FACSCalibur flow cytometer equipped with 
a 15-MW 488nm argon laser and 633nm red diode laser using 488 nm excitation with 530 nm 
and 590 nm bandpass emission filters to selectively probe and gate for respiring mitochondria, 
identified by JC-1 dye. The abundance was quantified as the mean ± SD number of events for 
the YWT, WT-80, OE-80, MKO-80, and SKO-80 transgenic mouse groups (n=5) for (A.) the 
subsarcolemmal and (B.) interfibrillar mitochondrial populations. [F*] denotes that a significant 
difference was observed for the global two-way ANOVA tests, but not for specific comparisons. 
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